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The aim of this thesis was to provide a better understanding of the final stages of PCa, 
metastatic castration resistant PCa and PCa death. We further aimed to address the 
consequences of possible undertreatment of elderly PCa patients. 
 
Patients and Methods 
Paper I: The study was a retrospective analysis of a consecutive sample of patients 
with mCRPC seen at the urological unit of a local hospital from 2000 to 2005, their 
mCRPC diagnosis based on rising prostate-specific antigen (PSA) during androgen 
depletion treatment (ADT). Several easily accessible parameters were identified and 
their prognostic value was tested. 
Paper II: The study included all 764 patients from Vestfold County who had PCa and 
who died in 2009-2014. The true cause of death of all patients was evaluated based on 
patient medical records. 
Paper III: Retrospective analysis of 117 patient records (PCa death, Vestfold County, 
M0 at diagnosis, no radical treatment). Decision rationales at diagnosis with regard to 
treatment were identified.  Local and systemic complications during the further course 
of the disease were registered. National data from the Cancer Registry of Norway 
(CRN, N=1874, ≥75 years at diagnosis, localized high-risk/ locally advanced PCa, 
WHO 0, diagnosed 2009-2017) were obtained and PCa specific survival was analyzed 
in patients who had received local treatment versus patients with no local treatment. 
 
Results 
Paper I: Median overall survival for the entire cohort of mCRPC patients was 12.3 
months (range 0.2-108 months), while 3-year survival was 16.9% (95% confidence 
interval 0.11-0.24). Two patients were alive at the end of follow-up. PSA doubling 





the onset of mCRPC and PSA nadir during ADT prior to the onset of mCRPC were 
strong predictors of overall survival.  
Paper II:  Over-reporting of PCa deaths in patients whose death certificate indicated 
that they died of PCa was 33% while under-reporting in the two groups who according 
to their death certificates died of other causes was 19% and 5%, respectively. The 
correlation between registered and observed causes of death was 0.81 (95% confidence 
interval 0.78-0.83). Misattribution of prostate cancer deaths increased significantly 
with patient age and decreasing Gleason score.  
Paper III: For the cohort of Vestfold patients age was the reason for choosing 
conservative treatment in 37% of patients (N=43), despite good health and functional 
status. Ninety percent of patients developed local complications attributable to PCa 
growth. National CRN data suggested a significant survival benefit for patients aged 
75-79 years who had received local treatment. 5-year cause-specific survival of 98.9 
percent (CI 96.7-99.7) compared to 90.8 percent in patients who had received no local 
treatment (CI 86.9-93.6). 
 
Conclusions 
Late stage PCa (mCRPC) is a heterogeneous condition with diverse survival. Its 
natural course can be defined by easily accessible parameters. 
PCa death reported on death certificates is unreliable particularly among the elderly 
and it is unsuitable as a stand-alone, population-based outcome measure in Norway. 
There are indications of undertreatment at diagnosis both in patients who later develop 
late-stage PCa and in patients who die of PCa and decisions with regard to radical 
treatment for patients with NMPCa are unduly influenced by patient age. The 
majority of elderly patients with high risk or locally advanced NMPCa who are not 
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Historically, the prospects for patients diagnosed with prostate cancer (PCa) were 
grim.  In a 1933 article Benjamin Stockwell Barringer -the first chief of urology at 
Memorial Hospital in New York City- lamented: “There is a peculiar fascination in 
backing lost causes. The reason for this is that medical science considers no cause 
wholly and irrevocably lost; it believes that there is no disease that which sooner or 
later may not be controlled. Prostatic carcinoma is today fairly firmly established in 
the lost-cause column.” He reported on 241 consecutive patients, 221 of whom had 
advanced or metastatic disease at diagnosis. Only 20 (8%) were deemed to have early 
stage PCa, meaning limited to the prostate gland or “prostate region” (1). This 
unsatisfactory state of affairs was also reflected in the scientific and clinical work of 
Hugh H. Young (head of urology at Johns Hopkins Brady Urological Institute from 
1897-1940), an early proponent of radical perineal prostatectomy, a procedure he had 
developed and published on for the first time in 1905 (2). In 1932, he summarized his 
experience: Over a period of twenty years, he had operated on just 42 patients, which 
implies that on average only two patients a year had had sufficiently localised tumours 
to warrant the procedure. Perioperative mortality was about ten percent in this series 
prior to the advent of antibiotics and proper aseptic procedures (3).  
Without effective treatment options such as hormone therapy, patients diagnosed with 
PCa usually died of the disease with an average survival of just 30 months (4).  
The suffering of these early patients and the often-forlorn efforts of the pioneers of 
PCa treatment have been motivation and warning for generations of urologists and 
oncologists. The prospects of the “lost cause”-patients have improved considerably, 
but for many patients the disease still carries great suffering and the outcome remains 
often fatal.  
The following pages contain a short summary of the current state of practice before 







1.1.1 Incidence and prevalence 
PCa is the second-most common cancer worldwide and by far the most common 
cancer in the developed world. Estimated incidence rates worldwide are increasing, 
from an estimated 900 000 new cases in 2008 (5) to 1.1 million in 2012 (6). More than 
two-thirds of these new cases (N~760 000) were diagnosed in developed countries 
where just 17 percent of the world male population live.  There is a broad consensus 
that changes in diagnostic practices, namely the introduction of PSA testing, have been 
a major cause of rising PCa incidence in the developed world (7). Countries with a 
PSA screening program, such as the United States and Canada, observed a PCa 
incidence peak in the first half of the 1990s followed by a sharp decline, while PCa 
incidence in other Western countries that adopted PSA screening more gradually 
appear to be rising still and no incidence peak has been observed yet (6).  
In Norway, PCa is the most common form of cancer among men, with approximately 
5000 new cases every year between 2011 and 2017. PCa incidence has risen 
considerably from 3848 cases in 2004 to the peak incidence year of 2016, when the 
Cancer Registry of Norway (CRN) reported 5253 new cases. The sharpest increase in 
PCa incidence in Norway was observed in 2011 when more than 700 extra cases were 
diagnosed compared to 2010 (8). Every year considerably more men are diagnosed 
with PCa than die of PCa. Consequently, prevalence numbers for PCa have more than 
doubled during the last one and a half decades: In 2004 just over 20 000 men lived 
with PCa in Norway. By 2017, this number had increased to 49 000 (8).  
 
1.1.2 Mortality and survival 
PCa was the fifth leading cause of cancer death worldwide with an estimated 300 000 
fatalities in 2012. Approximately half of the PCa deaths occurred in developed 
countries (N~140 000). The highest mortality rates were reported in the Caribbean and 
sub-Saharan Africa (6). The published data suggest a slight increase in PCa deaths 





development was driven exclusively by increasing PCa deaths in non-industrialised 
countries. In the developed world, PCa deaths have been either stable or decreasing 
(5).  
In Norway, absolute numbers of PCa deaths have been relatively stable during the last 
15 years (8): The number of PCa deaths reported in 2004 was 1026 and 934 in 2016. 
Most developed countries report similar findings. The reported decrease in PCa 
mortality of 2-4 percent annually for Norway and other developed countries during the 
last 10-15 years thus refer to age-adjusted mortality rates, rather than absolute PCa 
mortality (7). In the United States, the annual reduction in age-adjusted PCa mortality 
has recently flattened out (9).  
Relative survival is defined as the ratio of the proportion of observed survivors in a 
cohort of cancer patients to the proportion of expected survivors in a comparable set of 
cancer free individuals. Relative survival rates have improved significantly for PCa. In 
Norway for the period 1978-1982, the five-year relative survival for all PCa patients 
was less than sixty percent. These numbers had improved with more than fifty percent 
during 2013-2017 (five-year relative survival 94%) (10). There are some caveats 
related to survival in PCa that will be discussed later (see chapter 1.6) 
 
1.1.3 Age 
While patient age at diagnosis in Norway was stable for the time period 1983-1997 
(median age 74 years), it has since dropped considerably with a median age of 69 
years during the latest observational period (2013-2017) (10). However, this is not an 
expression of a true age shift nor the manifestation of a more aggressive behaviour of 
PCa, but rather the result of commonplace screening for early PCa of asymptomatic 
men. In the United States, where an organised screening program has been in place for 
more than two decades, the average age at diagnosis is 66 years (11). Figure 1 








In contrast to patient age at diagnosis, age at death has been rather unchanged over 
time and unaffected by screening. With a median age of 82 years at death, PCa as a 
cause of death in Norway affects mostly elderly men. The same holds true for other 
developed countries: In the United States, more than 70 percent of PCa deaths occur in 
men older than 75 years of age (11). Figure 2 illustrates the age of patients at death in 















Figure 1: Incidence of PCa in Norway in 2017 per age group. The red line indicates 
the median age of 69 years. 
Source: Cancer Registry of Norway. Adapted and modified from the annual report of 







1.2 Staging, grading and classification  
The heterogeneous nature of PCa and the need to better define the potential risk of 
individual tumours inspired Donald Gleason to design the histological grading that 
bears his name (12). For the clinician, the problem was described by Willet Whitmore 
in his Cancer paper from 1973: “Clinical judgment involves selecting the appropriate 
treatment . . . in the individual patient. Only with better methods for defining the 
natural history of the particular tumor, more sophisticated means for anticipating the 
life expectancy of the individual host, and good data on the effects of various 
treatments. . . will it be possible to inject more science into the extant art of treatment 














Figure 2: PCa deaths in Norway in 2017 per age group. The red line indicates the 
median age of 82 years. Source: Cancer Registry of Norway. Adapted and modified 





The decades that have passed since, have brought better staging, grading and risk-
classification systems to aid the clinician with the task of finding the appropriate 
treatment for the individual patient.  
 
1.2.1 Staging of prostate cancer 
As is the case for most cancers, PCa is staged using the Tumor Node Metastasis 
(TNM) classification by either the International Union Against Cancer (UICC) (14) or 
the American Joint Commission on Cancer (AJCC) (15). Originally, both 
classifications described exclusively the anatomical extension of PCa. In its 2016 
edition, the AJCC has introduced prognostic stage groups that incorporate non-
anatomic parameters, such as PSA and tumor grade (16). The EAU refers to the UICC 
TNM classification in its guidelines on PCa (17). The current criteria and definitions 
of the UICC clinical TNM classification are listed in table 1. 
 
T categorization 
In contrast to EAU risk classification, in the UICC classification, clinical staging of 
the primary tumor (cT) includes only findings from digital, rectal examination of the 
prostate (DRE). Information from imaging studies (e.g. capsular infiltration/ 
penetration) and from biopsies (e.g. tumor localization) should not be taken into 
account for cT categorization of PCa (16). It is likely that particularly MRI imaging 
will eventually improve cT staging of PCa, but due to a number of unresolved issues 
and somewhat conflicting and contradictory findings in clinical trials, imaging has not 














Table 1: Categories and definitions of the UICC clinical TNM staging system. 
Source: Reproduced from the EAU guidelines on prostate cancer (17) 
T - Primary Tumour 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Clinically inapparent tumor that is not palpable 
 
T1a Tumor incidental histological finding in 5% or less of tissue resected 
 
T1b Tumor incidental histological finding in more than 5% of tissue resected 
 
T1c Tumor identified by needle biopsy (e.g. because of elevated prostate-
specific antigen [PSA]) 
T2 Tumor that is palpable and confined within the prostate 
 
T2a Tumor involves one half of one lobe or less 
 
T2b Tumor involves more than half of one lobe, but not both lobes 
 
T2c Tumor involves both lobes 
T3 Tumor extends through the prostatic capsule* 
 
T3a Extracapsular extension (unilateral or bilateral) including microscopic 
bladder neck involvement 
 
T3b Tumor invades seminal vesicle(s) 
T4 Tumor is fixed or invades adjacent structures other than seminal vesicles: 
external sphincter, rectum, levator muscles, and/or pelvic wall 
N - Regional Lymph Nodes1 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
M - Distant Metastasis2 
M0 No distant metastasis 
M1 Distant metastasis 
 




M1c Other site(s) 
*Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is not 
classified as T3, but as T2. 
1 Metastasis no larger than 0.2 cm can be designated pNmi. 
2 When more than one site of metastasis is present, the most advanced category is 







The assessment of pelvic lymph nodes (LN) is in many respects the “blind spot” of 
PCa staging. The gold standard for lymph node evaluation is still extended pelvic 
lymph node dissection (ePLND), but it requires an invasive procedure and may 
nevertheless underestimate the extent of lymph node involvement (19). The risk of LN 
metastasis is commonly assessed using statistical nomograms (20, 21). Ideally, LN 
status would be assessed by imaging studies. However, traditionally available imaging 
has performed poorly (22). With the advent of novel molecular imaging techniques, 
LN staging has become more reliable and accurate. There is emerging evidence, that 
PSMA (Prostate-specific membrane antigen) PET/CT imaging for detection of LN 
metastasis is superior to other molecular imaging techniques (23).  
Currently there is no method to predict N-status reliably in PCa patients. However, it is 
likely that future imaging studies will provide sufficient sensitivity and specificity to 
replace ePLND as the gold standard for N-staging.  
 
M categorization 
Accurate staging and in particular accurate determination of metastatic status (M1 or 
M0) is vital for choosing adequate therapy for PCa patients. Extra nodal metastases 
from PCa develop primarily as sclerotic lesions in the bone while visceral metastases 
are rare in castrate-sensitive PCa (24, 25). There is clear evidence that the extent and 
the pattern of PCa metastasis has implications for the effects of local and systemic 
treatments (26, 27).  
According to EAU guidelines, imaging studies for detection of metastatic PCa ought 
to be reserved for high-risk patients (i.e. PSA levels ≥ 20 ng/ml, Gleason score ≥ 8, 
cT≥3) (17). International guidelines still regard bone scans as the standard imaging 
procedure for detection of bone metastasis and patient follow-up (17, 28). It is based 
on Technetium 99m-methyl diphosphonate (99mTc-MDP) that accumulates at points 





activity can thus be overlooked. The sensitivity of bone scans is generally acceptable  
with reported numbers of 62 to 89 percent (29, 30), while false-positive results can 
occur due to other metabolic disturbances in the bone that lead to increased osteoblast 
activity,  such as trauma and inflammation. This is the reason why bone scanning 
achieves low and unsatisfactory specificity levels (31, 32).  
The current EAU guidelines acknowledge that choline PET/CT, MRI and PSMA 
PET/CT are more sensitive in detecting bone metastases than bone scan and CT (17). 
However, since the benefit of maximum precision in detecting early metastasis is 
unclear, more advanced imaging techniques for primary M-staging are currently not 
endorsed (33).  
 
1.2.2 Grading of prostate cancer 
The original Gleason score from 1974 described the architectural composition of a 
tumor without any reference to cellular properties. The grading system, in combination 
with clinical staging, showed strong correlation with PCa death for high scores and 
differentiated patients with good prognosis from patients with lethal outcomes (12). 
The simplicity of the system and its strong predictive qualities lead to the rapid 
introduction of the Gleason score into clinical practice. It remains the cornerstone of 
PCa grading. 
The original Gleason score was revised in 2004 by a consensus group of urological 
pathologists (34) and in 2014 by an expert panel consisting of pathologists and 
clinicians (35). Figure 3 illustrates the resulting changes with regard to pattern 
evaluation. Particularly the changes made in 2004, while clarifying several areas of 
uncertainty, lead to a so-called Gleason shift with a general upgrading of tumors across 
the board. In a 2005 publication, Albertsen and colleagues showed that in a population 
of patients diagnosed with PCa in 1991-92, upgrades of Gleason scores outnumbered 
downgrades with a ratio of 4:1 when the original biopsy slides were reexamined 
according to the 2004 revision (36). This, in turn, has consequences for risk models 







According to the Gleason score revisions, Gleason grades 1 and 2 are no longer 
assigned. This means that the lowest Gleason score according to current practice is 
3+3=6. There is also consensus that Gleason 3+4=7a and Gleason 4+3=7b are 
different entities with different prognostic implications (37). A new grading system 
has thus been introduced which consists of grade groups 1-5 (International Society of 
Urological Pathology, ISUP): Gleason score 2–6 (Group 1); Gleason score 3+4=7 
(Group 2); Gleason score 4+3=7 (Group 3); Gleason score 8 (Group 4); and Gleason 
scores 9–10 (Group 5).  
The ISUP grade groups have been endorsed by the WHO and it is recommended that 
both Gleason score and ISUP grade group should be reported simultaneously for the 




Fig. 3: The original Gleason scoring system with corresponding tissue patterns (left) 






1.3 Diagnostic evaluation 
According to the EAU guidelines on PCa, the diagnostic workup of patients referred 
for evaluation, includes PSA blood test, digital rectal examination (DRE) and 
transrectal, ultrasound (TRUS) guided, systematic biopsies. The increasing role of 
MRI imaging in the diagnostic process is acknowledged (17). 
 
1.3.1 Prostate-specific antigen (PSA) 
Prostate-specific antigen (PSA) is a glycoprotein enzyme encoded by the KLK3 gene 
in humans. It is also known as gamma-seminoproteine or kallikrein-3 (KLK3). It is 
exclusively secreted by the epithelial cells of the prostate where it serves to liquefy 
semen and thus allows sperm cells to move effectively (39). PSA is detectable in 
serum in all men and is commonly elevated in the presence of benign disorders (e.g. 
benign prostate hyperplasia, infection) and PCa (40).  
 
PSA in diagnostic workup 
PSA levels correlate largely with PCa stage (41, 42) and are thus a valuable tool in the 
primary assessment of patients. PSA levels of >100µG/L strongly suggest metastatic 
disease (22).  
Used judiciously, PSA can be useful in assessing the need for further evaluations with 
biopsies and imaging studies. With the increasing use of PSA testing in primary health 
care, an elevated PSA level between 2 and 10 µG/L alone in the presence of normal 
findings on palpation should not automatically lead to a prostate biopsy in order to 
reduce over- diagnosis of PCa (17). Instead, patients should be counseled using risk 
assessment tools and nomograms that are validated for predicting indolent PCa (43). 
PSA density (PSA value divided by prostate volume) can serve as an important and 
easy-to-use trigger, as values below 0.15 in combination with a negative DRE indicate 
that the presence of aggressive PCa is unlikely (44). At the same time, it is important 
to remember that there is no “safe” PSA threshold, as clinical trials demonstrated that 





tumor volume, low PSA levels are indicative of aggressive disease associated with a 
bleak prognosis (46).  
 
PSA in screening and early detection of prostate cancer 
The goal of PSA screening is the detection of PCa at an early and potentially curable 
stage. There is consensus that the gradual reduction of PCa mortality in the US has at 
least in part been due to organized, PSA-based screening (47).  
The three major trials investigating the benefits of screening and early detection of 
PCa (PLCO Cancer Screening Trial, ERSPC, Gothenburg randomized population-
based prostate cancer screening trial) generated inconclusive and partially 
contradictory results (48-50). 
Screening and early detection of PCa remains thus one of the most debated topics in 
the urological community (51), particularly after the US Preventive Services Task 
Force (USPSTF) issued its D-recommendation in 2011, discouraging screening for 
PCa in healthy men (52). The increasing use of active surveillance has since let the 
USPSTF to soften its stance and the D-recommendation has been upgraded to a C-
recommendation. The task force’s current suggestion leaves the decision for or against 
screening for men aged 55-69 to the individual patient after careful information about 
the benefits and harms of PSA-based screening.  The new recommendation 
acknowledges that there may be a small survival benefit. However, the D-
recommendation for screening of men older than 70 years remains unchanged (53).  
In general, the debate is still unresolved if screening for PCa of asymptomatic, healthy 
men strikes the right balance between benefits and harms.  
 
1.3.2  Digital rectal examination  
Digital rectal examination (DRE) is still a cornerstone of clinical tumor staging. It 
assesses areas of increased firmness on the posterior surface of the prostate facing the 
rectum. The majority of tumors are located in this area. However, anterior tumors and 





in the absence of elevated PSA levels often indicate the presence of aggressive tumors 
(46, 55).  
 
1.3.3  Prostate biopsy 
Prostate biopsies need to reflect accurately the actual Gleason score to avoid 
misclassification.  
Standard of care is the ultrasound-guided, systematic biopsy performed by either the 
transrectal or the transperineal approach, sampling ten to twelve cores. However, since 
ultrasound does not visualize PCa reliably, the procedure is performed without 
information about the location of PCa. This biopsy strategy leads to over-diagnosis of 
clinically insignificant disease and under-diagnosis of potentially aggressive cancers 
(56).  
There is evidence that MRI-guided biopsies can enhance biopsy accuracy 
significantly, particularly after prior negative biopsies (57, 58). Targeted biopsies can 
be performed cognitively (by visualization of tumor or anatomical landmarks on 
TRUS), by real-time MRI targeted biopsy (with the patient placed in the MRI 
machine) or with MRI-TRUS fusion systems. All three approaches have overall cancer 
detection rates comparable to systematic biopsies, but with higher detection rates of 
clinically significant PCa and lower detection rates of clinically insignificant PCa (59).  
 
1.3.4 Imaging 
Grey-scale ultrasound (US) is useful in visualizing the prostate and in guiding 
systematic core biopsies. However, it does not reliably identify PCa in the prostate 
(60). It is therefore unlikely that US based strategies alone can replace systematic 
biopsies. New US based modalities such as sonoelastography and contrast-enhanced 
US have been introduced recently but are not recommended for routine use (17). 
The advent of multi-parametric MRI (MP-MRI) has gradually led to a paradigm shift 
in PCa imaging and the primary diagnostic evaluation of patients. Ahmed and 
colleagues demonstrated (PROMIS study) that MRI and targeted biopsies improved 





PCa (56). The results supported the notion that MRI of the prostate should be routinely 
performed prior to biopsies. Similar conclusions were reached by the PRECISION 
trial that showed that in biopsy-naïve patients, MRI prior to biopsy followed by MRI-
targeted biopsies was superior to systematic TRUS-guided biopsies in men at clinical 
risk for PCa (61). 
However, despite the introduction of a standardized system for reporting suspicious 
lesions on MRI (PI-RADS v2) (62), inter-observer variability remains high (63). The 
EAU in its most recent guideline update on PCa recommends MRI of the prostate prior 
to initial biopsies, but acknowledges that “systematic biopsy is an acceptable approach 
if mpMRI is unavailable” (17). 
 
1.4 Risk-stratification of prostate cancer 
The heterogeneous natural history of PCa makes defining risk categories both 
mandatory and challenging: On the one hand, there is a large group of indolent tumors, 
which are usually asymptomatic, have little or no metastatic potential and are not 
lethal during a normal life span. On the other side of the spectrum, we find extremely 
aggressive tumors, which develop in the course of weeks and months, metastasize 
early and lead to a rapid demise of the patient despite aggressive treatment (64).  
 
1.4.1  Risk-stratification models  
The recognition that not just anatomical, but also histological and biochemical 
parameters define patient outcome, lead to the introduction of integrated risk 
prediction models. Anthony D’Amico introduced the most commonly used risk 
stratification model in 1998 (65). He combined pre-treatment information on PSA, 
clinical T-stage (AJCC) and Gleason score to divide patients into low-, intermediate- 
and high-risk groups.  
Importantly, the model primarily defined risk for biochemical recurrence (BCR, 
increasing PSA levels over a defined limit) following therapy. The D’Amico risk 





(66). The EAU guidelines on PCa promote a three-tier risk-group system which 
follows the basic principles of the D’Amico risk classification (17). 
A further risk stratification system that has achieved widespread use in clinical 
practice is the Cancer of the Prostate Risk Assessment (CAPRA) score. It, too, 
integrates pre-treatment information on PSA, cT-stage and Gleason score and assigns 
low-, intermediate- and high-risk groups. The underlying scale of 0 to 10, however, 
allows for further differentiation of patient risk. The CAPRA score also appreciates the 
different prognostic outlooks of Gleason 7a and Gleason 7b, adding 1 and 3 points 
respectively to the final score (67). The CAPRA score, as the D’Amico 3-level system, 
predicts primarily BCR following treatment, but has also been demonstrated to predict 
metastasis, PCSM and overall mortality (OM) after surgery, radiation therapy and 
androgen deprivation therapy (68).  
 
1.4.2  Nomograms and calculators 
In the field of PCa, there is a plethora of prediction tools. Over one hundred 
nomograms have been designed that predict a great variety of outcomes such as: 
Positive biopsies with or without prior negative biopsies; prediction of pathological 
outcomes before surgery; prediction of biochemical endpoints before and after 
surgery; prediction of biochemical and clinical endpoints before radiation therapy and 
prediction of metastases and survival among patients with recurrent disease after 
primary treatment (69) . Particularly the Partin tables which  predict postoperative, 
pathological stage based on clinical stage, PSA and biopsy Gleason score, have 
reached widespread use in pre-therapeutical decision making (70).  
The majority of nomograms predict outcome based solely on tumor characteristics and 
do not take into account patient factors. This can complicate decision-making in a 
patient group with comorbidities and an often-limited life expectancy. A commonly 
used tool that takes into consideration both patient and tumor factors is the life-
expectancy-calculator by the Memorial Sloan Kettering Cancer Centre (MSKCC). It 
generates for a group of hundred men with given tumor characteristics and 





(see figure 4) (71). This model helps the clinician to illustrate for patients the actual 
risk their particular PCa represents in a setting that takes into account patient health 




1.4.3  Challenges with current risk-classifications 
In the common risk-stratification models, only PSA is a constant variable while 
Gleason grade and T-stage have been subject to significant changes over time. The 
modifications of the Gleason grading system that resulted in a general upgrading of 
tumors have already been outlined (see chapter 1.2.2). The increasing use of MRI has 
led to similar changes of the clinical T-staging (cT) of tumors. Particularly 
intermediate-risk tumors are prone to upgrading following MRI, affecting 
approximately 25 percent of patients (72).  
Gleason shift and upstaging of PCa by MRI thus regularly lead upgrading of tumors to 
a higher risk group. This has the net effect of improving the average prognosis in both 
groups, by removing the tumors with the worst prognosis in the lower risk group and 
Fig. 4: Illustration of risk of dying of untreated PCa (yellow) and dying of other 
causes (red) at 10 and at 15 years for an otherwise healthy 70-year-old man with 
PCa, clinical stage T1c, PSA 12, Gleason 7b. Black illustrates men alive.  





adding patients with a better prognosis than average in the higher risk group. This 




Two main treatment strategies have evolved over the last decades to improve the 
prognostic outlook of PCa patients:  
I. Early detection (see chapter 1.3.1) combined with local treatment with curative 
intent. 
II. Improvement of hormonal treatment and introduction of novel cytotoxic agents 
in the treatment of patients with advanced disease. 
Today, due to PSA testing of men, most patients present with localized PCa, which is 
potentially curable.  
 
1.5.1 Treatment of non-metastatic prostate cancer 
In principle, there are three therapeutic options for patients with non-metastatic PCa 
(NMPCa) depending on the stage and aggressiveness of the disease: Radical 
prostatectomy (RP), radiotherapy (RT) and active surveillance (AS). A fourth 
approach, watchful waiting (WW), is feasible only for patients with a very limited life-
expectancy either due to age or considerable comorbidity.  
 
Radical prostatectomy  
Patients treated with RP during the first half of the 20th century, were usually subjected 
to the procedure not to attempt cure but to achieve alleviation of obstructive symptoms 
(73).  
The role of surgery changed in 1983 when Patrick Walsh described a modified version 
of retropubic RP, which preserved the neuro-vascular bundle and consequently some 
form of erectile function in the majority of patients. The prospect of less side effects 





PCa due to PSA screening, led to a rapid increase in the number of RPs during the late 
1980s and early 1990s (74).  
RP entails the removal of the entire prostate gland and the seminal vesicles, 
preservation of the sphincter and the reestablishment of a drainage pathway by a 
vesico-urethral anastomosis. The goal of the procedure is the removal of the tumor 
with free surgical margins while preserving as much of the neurovascular bundle 
(erectile nerves) as possible to preserve erectile and continence function. Nerve-
sparing surgery can be performed in patients with localized PCa but may be associated 
with an increased rate of positive margins in patients with pT2 tumors if the procedure 
is performed bilaterally (75).  
In case of a preoperative risk of lymph node metastasis of five percent or more, as 
calculated by e.g. the Briganti nomogram (20) or the Roach formula (76), an extended 
pelvic lymph node dissection (ePLND) is indicated (17).  
RP can be performed by open, laparoscopic or robot-assisted techniques (RARP). 
There is consistent evidence that RARP is associated with shorter hospital stay and 
less blood loss (77, 78). However, there are no differences in short- or long-term 
functional and oncological outcomes between the three approaches (77-79). 
For almost two decades there was no evidence from randomized clinical trials that RP 
was associated with a survival benefit. In 2002, Holmberg and colleagues published 
results from the SPCG 4 trial that had randomized men with localized PCa diagnosed 
in 1989-1999 to either RP or WW. The participants had clinically and not PSA-
detected PCa. SPCG 4 demonstrated a significant reduction in PCSM but not in OM. 
The risk-reduction was most pronounced in men younger than 65 years at diagnosis 
and patients with intermediate-risk PCa (80). More recent and more mature data from 
the SPCG 4 trial showed better OS, reduced risk of metastases and less use of 
androgen deprivation therapy (ADT) favoring RP over WW (81).  
A corresponding trial (PIVOT), conducted by Wilt and colleagues who had 
randomized patients diagnosed in the early PSA era to either RP or WW, found no 
significant differences in OM and PCSM (82). The most recent trial, ProtecT, that 





ten years of follow up and no significant differences in OM and PCSM between the 
three groups. However, AS was associated with higher incidence of progression and 
metastasis (83).  
 
Radiotherapy  
Radiotherapy (RT) of the prostate as a palliative measure was first reported at the 
beginning of the 20th century (84). It utilizes ionizing radiation to target and kill cancer 
cells. Today, it is employed with both curative and palliative intent.  
Photon-based external beam radiotherapy (EBRT) and brachytherapy are the mainstay 
of treatment in a curative setting.   
 
External beam radiotherapy  
EBRT uses photons generated by a linear accelerator. EBRT was initially insufficient 
therapy because the first delivery systems did not generate enough energy to penetrate 
to deep-seated neoplasms such as PCa. First in the 1950’s, when higher energy cobalt 
machines managed to reach deeper levels of tissue, EBRT received renewed attention. 
The curative potential of EBRT for PCa was established by the trials of  Bagshaw and 
colleagues (85, 86). 
Today, standard treatment consists of fractionated radiation with individual doses of 
1.8–2.0 Gy and total dosages of 74.0–80.0 Gy (87). Dose escalation of up to 80 Gy is 
associated with increased toxicity and accuracy of radiation therapy within a moving 
organ has thus become increasingly important. Intensity modulated radiotherapy is a 
form of improved standard treatment, where different volumes of the irradiated area 
are treated with different doses, largely sparing surrounding healthy tissue (88). CT-
guided targeting of the prostate with the help of implanted markers (e.g. gold markers) 
allows for correction of both patient and organ movement, resulting in better targeting 
and potentially reduced side effects (89).  
EBRT in combination with neoadjuvant androgen deprivation therapy (ADT) has been 
standard of care for many years for patients with locally advanced NMPCa with 





with high-risk and locally advanced PCa, two to three years with neoadjuvant ADT are 
recommended (92), while patients with intermediate-risk PCa only require six months 
of ADT (93).  
Recent data published by the STAMPEDE trial group indicated that a subgroup of 
patients with metastatic PCa might may benefit from EBRT of the prostate in 
combination with systemic therapy in terms of survival (26). 
 
Brachytherapy 
The principle of low-dose brachytherapy entails implantation of permanent radioactive 
seeds. The initial trials on brachytherapy with open implants of iodine-containing 
titanium cylinders demonstrated that the procedure was feasible, but there were serious 
challenges with inconsistent dose distributions and major complications as a 
consequence with high rates of local failure (94). First in 1983, with the introduction 
of ultrasound-guided implantation of radioactive seeds (95), did brachytherapy 
establish itself as a viable treatment alternative for patients with localized PCa (96). 
However, only patients with localized low-risk or low-volume intermediate risk are 
eligible for low-dose brachytherapy (97) with active surveillance as the preferred 
option for these patients today (see below).  
With high-dose brachytherapy, a radioactive source is temporarily introduced into the 
prostate via the perineum. Radiation is delivered either in single or multiple fractions. 
One randomized clinical trial reported promising results of combined high-dose 
brachytherapy plus EBRT versus EBRT alone (98), but the results need to be 
interpreted with caution since the control group (EBRT alone) was treated with sub-
standard radiation doses (55 Gy, 20 fractions).  
 
Side effects of radical treatment 
Radical treatment of PCa has side effects that can have a significant impact on 
patients’ quality of life (99). This was one of the motivations behind the introduction 






A recent publication of patient-reported outcome measures from the ProtecT trial 
demonstrated that patients after RP had consistently higher rates of urinary 
incontinence than after RT or under active surveillance (AS) (100). Forty-six percent 
of patients used pads six months after treatment (AS: 4%, RT: 5%). 
After six years of follow-up, 17% of men in the RP group were using pads (AS: 8%, 
RT: 4%). At baseline, 67% of patients reported erectile function sufficient for 
intercourse. A significant decline was observed in all groups after six months (AS: 
52%,  RT: 22%, RP: 12%). Erectile function remained worse in the RP group during 
the entire study period despite some recovery.  
RP and AS did not affect bowel function, bowel bother scores and bowel-related 
quality of life, while these outcomes were worse in the radiotherapy group, particularly 
at 6 months. However, after two years, RT patients only experienced more bloody 
stools while all other parameters were comparable to RT and AS.  
Studies in selected patients from high-volume centers show better results for RP than 
ProtecT with preserved sexual function in over eighty percent of patients (101). 
 
Active surveillance  
Active surveillance (AS), also known as active monitoring or deferred treatment, has 
become an increasingly acknowledged alternative for selected patients with localized 
PCa. Particularly patients with PCa diagnosed on the basis of an elevated PSA without 
any other symptoms or findings, will in many instances not benefit from radical 
treatment (102). AS offers patients a path to avoiding the side effects that come with 
radical treatment while reducing risk by continuous and close surveillance of the 
tumor. In contrast to watchful waiting, these patients will be candidates for radical 
treatment if their tumors show signs of progression beyond predefined thresholds.  
Klotz and colleagues from Toronto, Canada, conducted one of the largest studies 
(N=980) on AS to date and with the longest follow-up. Inclusion criteria were stage 
T1c or T2a, a PSA ≤ 10 ng/mL and a Gleason score of ≤ 6 at diagnosis and age 
younger than 70 years.  For patients older than 70 years, a Gleason score of seven was 





After a median follow-up of 6.3 years (range 0-20 years) 30 patients (3%) developed 
metastasis and 15 patients (1.5%) died of PCa. Disease-specific survival after 10 and 
15 years was 98 and 94 percent respectively. Twenty-seven percent of patients 
underwent radical treatment due to progression (104).  
Researchers from Johns Hopkins conducted a comparable AS trial in the US with a 
large cohort of patients and long follow-up. Patients eligible for the trial had to fulfill 
more stringent inclusion criteria than the Toronto patients and the disease-specific 
survival was accordingly higher. After 10 and 15 years of follow-up disease-specific 
and metastasis-free, survival was close to 100 percent. Thirty-six percent of patients 
underwent radical treatment eventually, of which approximately 25 percent in the 
absence of progression (patient preference) (105).  
Acceptance of AS has been slow, partly due to reports of adverse pathological features 
(higher Gleason/ T-stage in prostatectomy specimens) in patients who were eligible for 
AS but opted for surgery instead (106).  However, there is little evidence that these 
adverse pathological outcomes translate into adverse clinical outcomes (107). 
The role of MRI in increasing accuracy at diagnosis and safety under follow-up for 
patients under AS remains currently undefined (108, 109). 
In general, AS appears to be a safe alternative to radical therapy for most patients with 
low-risk PCa and an option for selected patients with intermediate-risk PCa.  
 
Watchful waiting 
There is still some confusion about the role of watchful waiting (WW) as compared to 
AS and the terms are often used synonymously. In contrast to AS, patients under WW 
are not candidates for radical treatment, with hormone therapy as the primary 
treatment option if their PCa becomes symptomatic or metastatic. It is frequently the 
preferred option for the oldest patients and patients with multiple comorbidities.  
It is also important to bear in mind that the landmark studies that tested radical 







1.5.2 Treatment of metastatic prostate cancer 
The incidence of metastatic PCa at diagnosis in the US is approximately 50 percent 
lower now than in 1988 and there is broad consensus that this stage shift is due to 
aggressive PSA screening. However, during the last decade the incidence of metastatic 
PCa has stabilized which means that a considerable number of patients still present 
with metastasis at diagnosis (110). In Norway, approximately half of the patients who 
later die of PCa initially present with metastatic disease (111). In a recent publication, 
metastatic patients in the control arm of the STAMPEDE trial (ADT only as primary 
therapy) had a median OS of 3.5 years (112) .   
 
Hormone therapy 
ADT has been the mainstay of treatment for metastatic PCa for decades. Surgical 
castration used to be the primary treatment option but has since been largely replaced  
by other therapeutical agents that achieve similar outcomes: Luteinizing hormone-
releasing hormone (LHRH) antagonists and LHRH agonists (113). However, for 
patients with impeding spinal cord compression, surgical castration or LHRH agonists 
are recommended as primary treatment because of their immediate effect on 
testosterone levels and tumor growth (17).  
In the metastatic setting, monotherapy with non-steroidal anti-androgens has no 
accepted place with evidence pointing to unfavorable outcomes compared to LHRH in 
terms of OS, clinical progression and treatment failure (114). However, anti-androgens 
appear to convey a moderate survival benefit in combination with LHRH (complete 
androgen blockade) (115).  
Intermittent ADT is a treatment option in patients with good response to hormone 
therapy in order to alleviate the side effects of ADT. Intermittent ADT appears to be 
non-inferior to continuous ADT (116).  
 
Other systemic therapies in metastatic prostate cancer 
Primary treatment of metastatic PCa has undergone significant changes during the last 





(GETUG-15, CHAARTED, and STAMPEDE) have demonstrated the importance of 
adding docetaxel to ADT as primary treatment for patients with metastatic PCa (27, 
117, 118). While GETUG-15 failed to show a significant survival benefit, both 
CHAARTED (Median OS 57.6 vs 44 months, HR 0.61) and STAMPEDE (Median OS 
60 vs 45 months, HR 0.76) demonstrated conclusively a significant survival benefit of 
the combined treatment approach. The reason for the conflicting outcomes in these 
three trials is currently unknown. The EAU guidelines on PCa strongly recommend the 
addition of docetaxel to ADT in the treatment of PCa patients with metastatic disease 
(17). Two further trials documented comparable effects of abiraterone when given in 
combination with ADT in hormone-naïve M1 patients (119, 120) and their use is 
equally recommended by the EAU in patients unfit for chemotherapy.  
 
Local treatment of the prostate in metastatic disease 
In a recently published trial from the STAMPEDE group, with over 2000 men 
randomized to either standard of care (SOC) or SOC plus radiotherapy to the prostate, 
the latter combination conveyed no significant survival benefit in unselected patients. 
However, patients with a low metastatic burden showed improved survival after 
radiotherapy to the prostate (26).  
 
 
1.5.3 Treatment of metastatic castration-resistant prostate cancer 
Metastatic, castration-resistant PCa (mCRPC) is the preterminal stage of PCa. 
Castration-resistant PCa is currently defined by either biochemical progression with 
three consecutive rises in PSA one week apart resulting in two 50% increases over the 
nadir, or by radiological progression with the appearance of either two or more new 
bone lesions on bone scan or a new soft tissue lesion in patients on ADT. The 
definition of CRPC requires a serum testosterone at castration level with values of 50 
ng/dl or less (17). Until the introduction of docetaxel, roughly fifteen years ago, no 







The simultaneous publication of the SWOG 99-16 and TAX 327 2008 trials in 2004 
represented a watershed moment in the treatment of patients with mCRPC which had 
traditionally shown little response to conventional chemotherapy regimens. Both 
studies showed a significant OS benefit of two to three months for patients who 
received docetaxel every three weeks plus prednisolone 5mg BID compared to 
controls (121, 122). Therefore, docetaxel has become primary treatment for 
chemotherapy-naïve mCRPC patients.  
More recently, two additional substances have been added to the therapeutic arsenal 
for chemotherapy-naïve mCRPC patients: Abiraterone and enzalutamide. Both 
substances target pathways related to the androgen-receptor and are commonly 
referred to as second-generation antiandrogens.  
Abiraterone demonstrated a significant reduction of radiographic progression and an 
OS benefit of 35 months in the treatment group versus 30 months in the control group 
(123).  
The PREVAIL trial found similar results for enzalutamide in chemotherapy-naïve 
patients with an OS benefit of approximately four months and a reduction of 
radiographic progression of 68 percent (124).  
 
Sequencing and second-line treatment 
Almost all patients with mCRPC will progress despite effective first-line treatment. 
Further significant delays of disease progression can be achieved by different 
sequences of second-line therapies. The benefits of second-line therapies need to be 
weighed against side effects, realistic treatment objectives, quality of life, costs and 
patient age and comorbidity.  
Two large randomized, placebo-controlled trials (COU-AA-301, AFFIRM) 
demonstrated significant survival benefits of 4-5 months in patients with progressive 
disease after docetaxel therapy who had received abiraterone (COU-AA-301) or 





both therapies were superior compared to placebo in terms of secondary objectives 
such as soft-tissue response, biochemical (PSA) and clinical progression.  
Cabazitaxel is a second-generation taxane with effect in docetaxel-resistant PCa. The 
TROPIC trial (randomized phase III) demonstrated a survival benefit of cabazitaxel of 
approximately 2.5 months compared to SOC (127). However, toxicity and cost are 
factors that have so far hampered the widespread adaptation of this treatment option.  
Radium-223 is an α-emitter with high affinity to bone. A large randomized, placebo-
controlled phase III trial (ALSYMPCA) demonstrated a survival benefit of Radium-
223 in patients who progressed on or were unfit for docetaxel of roughly 3.5 months 
compared to placebo. It also prolonged time to first skeletal event, lead to 
improvement in pain scores and in quality of life (128).  
 
1.6 Knowledge gap 
Defining patients’ risk for dying of PCa and finding adequate and effective ways of 
reducing that risk remains a challenge for the clinician, despite the introduction of 
advanced diagnostic tools. 
We usually assess and predict risk through the lens of risk-stratification models and 
nomograms. However, to be able to grasp the risk PCa patients are exposed to 
completely, we need to have a thorough understanding of both the outcome that we 
aim to change and our outcome measures and their limitations. Furthermore, 
appreciation of the natural course of PCa at its various stages is necessary to make 
effective and meaningful treatment decisions for our patients. 
 
1.6.1 Natural course of prostate cancer 
In order to affect outcomes, it is important for the clinician to understand the natural 
course of PCa and to appreciate when and how it can be altered by therapeutic 
interventions.  
Although we have for PCa in general a relatively good picture of the natural course of 
the disease from the first diagnosis to death on a population level (129), important 





The preterminal stage of PCa is mCRPC. By extension, reducing patients’ risk of 
developing mCRPC would equally reduce the risk of dying of PCa. However, the 
“baseline” natural course of mCRPC patients without life-prolonging treatment 
(Docetaxel, Abiraterone, etc.) is currently undefined on a population base and our 
knowledge about this patient group stems from the control arms of clinical, 
randomized trials with significant patient selection.  
Our perception of the natural course of PCa is also influenced by patient factors, 
namely patient age and comorbidities. High patient age and/ or several comorbidities 
can lead the clinician to conclude that patients will not live long enough to suffer the 
negative impact of their PCa in terms of morbidity and mortality. In Norway 15-20 
years ago, this understanding of patient factors lead to relatively strict age limits for 
radical treatment with very few patients >75 years receiving such treatment at the time 
(8). If this policy benefited the elderly patients has to our knowledge not been 
evaluated.   
 
1.6.2 Mortality and Survival 
Survival is generally an unsuitable outcome measure in most PCa patients. Rising PCa 
incidence numbers due to PSA testing have likely led to a dilution effect where better 
survival data are the result of adding new patient groups with a considerably better 
prognosis rather than real improvements in treatment and outcome. However, survival 
can be a good measure of treatment effects in more stable subgroups of PCa patients, 
e.g. de-novo metastatic (M+) PCa patients. A recent report showed no marked 
improvement of survival for these patients over a 20-year period (130). 
The main outcome measure of PCa treatment at all stages is PCa specific-mortality 
(PCSM). Most Western countries have seen a gradual decline of age-adjusted PCSM 
over the last ten to twenty years, as previously outlined (see chapter 1.1.2). 
PCSM is reported age-adjusted to allow for comparisons of PCa population over time 
and between countries.  A complicating factor is the definition of PCa death. In 
clinical trials, PCa death is commonly determined by a cause-of-death committee 





participant (131, 132). On a population level PCa mortality numbers are based 
exclusively on death certificates of deceased men. It is crucial for the quality of 
population-based PCa mortality numbers that death certificates contain reliable 
information on patients’ death.  
Misattribution of cause of death may for instance have implications for the relatively 
high PCa mortality in Norway compared to other countries. However, to date thorough 
audits of death certificates have not been conducted.  
 
1.6.3 Summary 
To provide patients with good advice and a realistic picture of the nature and the 
inherent risk their PCa represents, we ourselves need to have a better understanding of 
the final stages of PCa and PCa death. In particular, we need to 
- Broaden our understanding of mCRPC 
- Evaluate if current PCa mortality statistics give a realistic picture of outcome in 
Norway 
- Better understand the characteristics of patients who die of PCa and the course 
of their disease 
- Evaluate the effects of treatment decisions based on strict patient criteria on the 





2.  Aims of the thesis 
 
General aims 
The aim of this thesis was to provide a better understanding of the final stages of PCa, 
metastatic castration resistant PCa and PCa death. We further aimed to address the 
consequences of possible undertreatment of elderly PCa patients. 
 
Paper I 
The aim of this study was to determine survival in unselected patients with metastatic 
castrate-resistant prostate cancer (mCRPC), who never received life-prolonging 
treatment. The study aimed to define the natural course of mCRPC without life-
prolonging treatment and provide prognostic factors for better risk-stratification in a 
population representative for Norway. 
 
Paper II 
PCa mortality statistics are based on information from death certificates. This study 
aimed to evaluate the quality of death certificates related to PCa and assessed the level 
of misattribution on a population level.   
 
Paper III 
In paper III we aimed to define the rationales for choosing conservative treatment in a 
cohort of men with NMPCa, the consequences in terms of local complications and the 
need for systemic treatment. On a national level we aimed to study survival of elderly 
patients (>75 years) who had received local therapy at diagnosis compared to patients 










3. Material and methods 
 
3.1 Permissions and ethical considerations 
All papers were submitted and approved by the Regional Committee for Medical and 
Health Research Ethics in South-Eastern  Norway  (REK South East) (REK number, 
paper I: S-06282a; paper II and III: 2014/2203) 
 
3.2 Study Population 
All three papers included retrospective analyses of PCa patients in Vestfold County, 
Norway. Vestfold County has approximately 240 000 inhabitants (Mean 2009-14: 
235 000) representing roughly five percent of the Norwegian population. There is one 
hospital (Vestfold Hospital Trust) serving the entire county with the exception of the 
peripheral municipalities of Sande and Svelvik. Vestfold Hospital Trust has a 
urological department with eight senior consultants who are responsible for treatment 
and follow-up of PCa patients in Vestfold County. At the time of the study, there were 
no urologists or oncologists in private practice. Thus, almost all relevant information 
about patients’ PCa treatment and follow-up could be obtained from the hospital’s 
patient records allowing for high quality, population-based retrospective studies. 
The male population of Vestfold County has a higher proportion of men ≥70 years 
compared to the rest of the country. Other relevant socioeconomic factors are 
comparable.  
Table 2 lists the characteristics of the male population of Vestfold County in 
comparison to the male population of the entire country. 
 









Table 2: Sociodemographic comparison between the male population of Vestfold 
County and Norway for the years 2009-2014. Unless otherwise stated, the numbers 
are the mean of the observations for the years 2009-2014.  
 Vestfold County Norway 
Population, males (mean 2009-2015) 117,088 2,497,670 
% of the male population >= 70 years 9.7 8.8 
Estimated life expectancy (years), males (2011-
2015) 
79.3  79.7 
ASDR all causes, males 1220/100,000 1209/100,000 
ASDR prostate cancer (official statistics) 71/100.000 67/100.000 
Percentage of males >16 years with more than 
12 years education 
24.5 26.9 
Occupation, males (2011-2015)   
  Predominantly non-manual, ISCO group 1-5 
(%) 
52.7 52.8 
  Predominantly manual, ISCO group 5-10 (%) 47.3 47.2 
Mean gross income, persons (M+F) above 17 
years (NOK) 
364.100 383.700 
Source: Statistics Norway, Norwegian Cause of Death Registry; Norwegian Institute 









Vestfold County hospital’s patient administrative system was used to identify all 
patients registered with diagnosis C61 (Prostate cancer, International Classification of 
Diseases, 10th revision, ICD-10), who had been seen at Vestfold Hospital Trust 
between 2000 and 2005 (N=1460). The medical records of these patients were 
screened to identify patients with mCRPC (N=168). Thirty-eight patients who had 
received docetaxel, abiraterone, enzalutamide or radium-223 were excluded from the 
study, leaving 130 patients for further evaluation. 
According to guidelines at the time, CRPC was defined by a continuous rise in serum 
prostate-specific antigen (PSA) levels, progression of pre-existing disease and/or the 
appearance of new metastases (133). The date of the first rising PSA during either 
chemical (LHRH) or surgical ADT followed by continuously rising PSA values was 
defined as the onset date of mCRPC. For patients who had non-measurable PSA 
values during ADT, the first PSA value above 0.1 mg/l was defined as the onset of 
CRPC. Supportive treatment that was SOC consisted of bicalutamide, prednisolone, 
biphosphonates and/or palliative radiotherapy. 





The observation time ranged from the onset date of mCRPC until death or 31 
December 2012, whichever event occurred first. 
 
Paper II 
For the six-year period 2009–2014, names and dates of birth of all deceased men in 
Vestfold County, registered with either PCa as the immediate/underlying cause of 
death (PCD, N=341) or other significant condition at death (OCD, part II of the death 
certificate, N=127) were obtained from the Norwegian Institute of Public Health.  
Furthermore, data on all deceased men in Vestfold County with a diagnosis of PCa, 
but whose diagnosis was not mentioned on the death certificate were obtained from the 
Cancer Registry of Norway (CRN). The latter group of patients was designated PC-
DCneg (prostate cancer, no mention of PCa on death certificate).  
The three study populations are illustrated in figure 6.  
 
Paper III 
In the study population of paper II, we identified 139 patients who had non-metastatic 
PCa (NMPCa) at diagnosis, but who died of PCa. In the first part of paper III we 
investigated 117 (84%) of these patients who had not received local/ curative 
treatment. Metastatic status was determined by the imaging method available at the 
time of diagnosis (bone scan, CT, MRI).  
For the second part of paper III, CRN provided national data on 1874 patients who 
were seventy-five years or older at diagnosis, had localized high-risk or locally 
advanced PC, normal functional status (WHO performance status 0) and had either 
received effective local treatment or no local treatment in the time period 2009-2017. 
We defined effective local treatment as radical prostatectomy ≤12 months after 
diagnosis or radiation of ≥60Gy to the prostate ≤15 months after diagnosis following 
CRN selection procedures. 









All data were extracted from patient records.  
Prior to the onset of mCRPC:  
- Date of PCa diagnosis, age, metastatic status and Gleason score at diagnosis 
- PSA nadir during ADT, duration of hormonal treatment until onset of mCRPC 
At the onset of mCRPC:  
- PSA, alkaline phosphatase and hemoglobin 
- PSA doubling time (PSA nadir value plus next two consecutive PSA),  
- Date and vital status at last observation.  
We defined “effective hormone time” as the time from initiation of any hormonal 
treatment (including bicalutamide monotherapy) until the first rising PSA under ADT 
with persistently rising values afterwards. 
Fig. 6: Flow chart of the study populations of paper II and paper III. PCa: prostate cancer, 





For patients registered with WHO classification instead of Gleason score (51%), we 
performed the following conversions: WHO I to Gleason 6, WHO II to Gleason 7 and 
WHO III to Gleason 8. We estimated PSA doubling time based on PSA values early 
after the diagnosis of mCRPC using the online calculator of the Memorial Sloan 
Kettering Cancer Center (134).  
We defined cut-off values for age at diagnosis, effective hormone time, PSA doubling 
time, PSA at CRPC and PSA nadir by trichotomization of their statistical distributions. 
For the Gleason score analysis, patients with a high-risk profile (Gleason 8–10) were 
separated from a group with expected lower risk (Gleason ≤7). The levels of 
hemoglobin were dichotomized with the lower limit value of the normal range as the 
cut-off value (≥13.4 vs <13.4 g/dl) 
 
Paper II 
The main challenge in this study was to specify the cause of death as correctly and 
objectively as possible in patients with often-complex medical histories. We thus 
formed a review committee consisting of three urologists and one oncologist. Patient 
hospital records provided sufficient information on medical histories for the great 
majority of patients. For twelve patients, we obtained additional information from 
nursing homes or family doctors. We conducted three consecutive reviews of the study 
population. The first review served as a filtering process to identify patients with an 
unambiguous, immediate cause of death and a clear underlying disease process, 
separating out patients ascribed as dead either from PCa (PCD) or as dead from other 
causes (OCD). The first author conducted this review, with a blinded audit of 50 
random patients in the sample by two other committee members demonstrating perfect 
correlation. We assumed PCD when the immediate cause of death was caused by 
systemic or local complications of the disease process or cancer-directed treatment and 
comorbidities were either absent or of obvious minor importance. We defined OCD by 







We included patients who we could not assign to either of the above categories in the 
second review for further evaluation. Patients with autopsy results were registered with 
the underlying cause of death given on the autopsy report, and no further review of the 
cause of death was conducted (N=16). 
 
For the second review, committee members independently analyzed patient histories 
unaware of the conclusions from the other reviewers. We assigned the following 
categories when answering the question of whether the patient’s death was due to PCa: 
‘Yes/No’ (preferable category), ‘Likely/Unlikely’ (if a definite answer was not 
possible) or ‘Not possible to determine’ (if any qualified answer was impossible to 
Table 3: First review of patient history - definition of death of other causes and 
results for patients with prostate cancer as an immediate or underlying cause of 
death (PCD), N=328 
 
No histological or clinical diagnosis of prostate cancer 
 
15 (4.6 %)  
Watchful waiting with no significant disease activity  13 (4 %) 
Previous radical treatment with no disease recurrence 
and an immediate cause of death not related to 
treatment 
 5 (1.5 %) 
Hormone therapy with complete response to treatment 
and an immediate cause of death unrelated to hormone 
therapy, and other 
 33 (10.1 %) 
Other, clinically more significant metastatic 
malignancies 
 
 4 (1.2 %) 






give, owing to numerous and competing comorbidities). We included patients with 
conflicting conclusions in the third review. 
For the third review, we discussed patients whose underlying cause of death was still 
undetermined in consensus meetings with all members of the committee present. We 
reviewed patient histories in plenum and reached a consensus decision, which all 
committee members could agree upon. Assignment of labels followed the same 
principles as outlined under the second review of patient history. 
For the end result, we collapsed patients with the label ‘Yes’ or ‘Likely’ into category 
‘Yes’ (dead from PCa). Accordingly, we collapsed patients labeled ‘No’ or ‘Unlikely’ 




We deducted the rationales for choosing radical versus non-radical treatment from the 
patient records at the time of diagnosis based on the stated or implied reasoning of the 
treating doctor. We assigned patients to two groups according to the decision rationale: 
Patients who had not received curative treatment due to their age (NoTreat/Age) and 
patients who had not received curative treatment due to other reasons (NoTreat/Other). 
We assessed patient performance status retrospectively using the Eastern Cooperative 
Oncology Group score (ECOG) (135) and recorded comorbidity using the Charlson 
comorbidity index (CCI) and estimated 10-year survival using the age-adjusted 
Charlson-score (CS) (136).  
We collected data on survival, tumor characteristics at diagnosis, use of systemic 
therapy/ radiation to bone/ prostate and local complications during the course of the 
disease from patient records. 










All statistical analyses of the Vestfold patient cohort were performed using SPSS for 
Windows, versions 18, 22 and 23 (IBM Corp., Armonk, NY, USA) and the R 
statistical package (137).  
Paper I: We tested differences in baseline variables using Mann–Whitney tests and 
calculated survival curves, three- and five-year survival and median survival using 
Kaplan–Meier estimation, with 95% confidence intervals (CIs) and 5% significance 
level to assess statistical uncertainty and significance. We calculated Kaplan– Meier 
confidence intervals using log-minus-log transformation. Factors that were statistically 
significant in the univariate analysis were included in the multivariate Cox regression 
analysis. We used Markov chain, Monte Carlo (MCMC) multiple logistic regression 
imputation to check the effect of missing values on Cox regression estimates.  
Paper II: We described baseline data and PCa death misclassification rates by median, 
range, percentages, and calculated confidence intervals (CIs) for percentages using 
Wilson score interval with Yates’ continuity correction. The effect of age and study 
year on the risk of misclassifying cause of death was studied by binary logistic 
regression. Subgroup analysis was performed by dividing patients into seven age 
groups (<65, 65–70, 70–75, 75–80, 80–85, 85–90, and >90 years). We calculated 
correlation between the cause-of-death methods using Cohen’s kappa. 
Paper III: We described baseline data by median, interquartile range and percentages.  
For the CRN data, cause-specific survival was estimated using the Kaplan-Meier 
estimator, where the 95 % confidence intervals were based on Greenwood’s formula. 
The patients’ follow-up time was left-truncated at 15 months after their date of 
diagnosis, since local treatment was defined as treatment within 15 months after 
diagnosis. Within each age group, a likelihood ratio test was performed to test the 
significance of local treatment using Cox proportional hazards models adjusting for 







4.1 Paper I 
The great majority of the 130 patients who were treated for mCRPC at Vestfold 
Hospital Trust in 2000-2005 were over 70 years old when diagnosed with PCa 
(median age 73 years, range 46–89 years). Sixty-six percent (N=86) presented with 
metastatic disease at diagnosis.  
At the onset of mCRPC, patients were 75 years old, a median time of 19 months 
(range 0-134 months) after the initial PCa diagnosis. Effective hormone time lasted for 
a median of 17 months (range 0-108 months). Twenty-eight patients were initially 
followed with watchful waiting (time from diagnosis until initiation of any therapy >6 




Median survival after onset of mCRPC was 12.3 months (range 0.2–108 months, 95% 
CI 8.5–16.1). Two patients were alive at the end of the observation time. Eight patients 
(6 %, 95% CI 0.03–0.11) lived for 5 years or longer. Eight patients with a very short 
effective hormone time of 3 months or less had a median survival of only five months 
after onset of mCRPC (range 3.3–10.9 months, 95% CI 4.4–5.8). Figure 7 illustrates 
patient survival after the onset of mCRPC.  
 
4.1.2 Prognostic factors 
In univariate analyses, the following variables were associated with a favorable 
prognosis: PSA nadir during ADT of less than 1.1 mg/l, PSA doubling time of more 
than 3 months during the early period of mCRPC, and alkaline phosphatase and 
hemoglobin within the normal range at the onset of mCRPC. Effective hormone time 
of less than 10 months, PSA doubling times of less than 1.6 months or a PSA nadir of 





and metastatic status at diagnosis and PSA at mCRPC had no significant impact on 
survival. In the multivariate Cox-regression model, effective hormone time did not 
reach statistical significance (p = 0.5). On the other hand, PSA doubling time, PSA 
nadir during ADT, hemoglobin and alkaline phosphatase levels at CRPC remained 
strong prognostic factors.  
 
4.2 Paper II 
The majority of patients in all three study groups (PCD, OCD, PC-DCneg) were 
elderly (>80 years) at death. The median age at death was 84 years in all groups. In the 
PCD group, 21 percent of patients were younger than 75 years at death, with 
corresponding numbers of 14 percent in the OCD group and 16 percent in the PC-
Fig. 7: Kaplan–Meier curve with median, three- and five-year overall survival of 





DCneg group. Fourteen percent of patients in the PCD group, 20 percent in the OCD 
group and 14 percent in the PC-DCneg group were older than 90 years at death. 
 
4.2.1 Patients registered as dead of prostate cancer (PCD group) 
The final results of the review process demonstrated that 32 percent (N=105) of the 
328 patients in the PCD group had died of other causes than PCa. Logistic regression 
demonstrated a statistically significant increase in misattribution rates with increasing 
age in the PCD group (p<0.001, OR 1.8 per 5 years, 95% CI 1.4–2.1). Among patients 
younger than 75 years, 10 percent (7/70) were incorrectly labeled as dead from PCa 
while the misattribution rate increased to 63% in patients aged 90 years and older 
(29/46). Misattribution of cause of death per age group in the PCD group is illustrated 
in Figure 8.  
  
4.2.2 Patients registered as dead of other causes (OCD group) 
The final results of the review process indicated that 18 percent of patients (N=23) had 
actually died of PCa. Logistic regression showed a statistically non-significant 
decreasing trend of misattribution by age in the OCD group (p=0.33, OR 1.2 per 5 
years, 95% CI 0.9–1.6). 
 
4.2.3 Patients with prostate cancer, not registered on the death certificate 
(PC-DCneg) 
Among the 310 PC-DCneg patients, the review process identified 5 percent (N=14) 
who had died of PCa. 
 
4.2.4 Overall misattribution 
Underreporting of PCa deaths in the OCD and PC-DCneg groups was 18 and 5 percent 
respectively, while over-reporting in the PCD group was 32 percent. The net result 
was an over-reporting of PCa deaths of approximately 20 percent. The correlation 





0.83), with Cohen’s kappa (0.4, 95% CI 0.3–0.5) showing a moderate correlation 




4.3 Paper III 
4.3.1 Vestfold cohort 
Of the 117 patients from paper II who were included in the study (M0 at diagnosis, no 
curative treatment), 73 (62%) were initially treated with hormones, while 44 patients 
(38%) were followed with WW.  
Further analysis of the decision process identified age as the main reason for 
abstaining from radical treatment (NoTreat/Age, N=43, 37%). Patients in this subgroup 
Fig. 8: Patients registered as dead from PCa (PCD) per age group: patients actually 
dead from PCa (blue), patients dead from other causes (green) and patients whose 





represented 17 percent of the total PCa mortality in Vestfold County during the study 
period. All rationales for choosing hormone therapy or WW (NoTreat/Other, N=74, 




The median age at diagnosis in the NoTreat/Age and NoTreat/Other groups was 79 
and 70 years respectively, and the median time from diagnosis to death seven and 
eight years. Most patients in the NoTreat/Age group were in good functional shape at 
the time of diagnosis with an ECOG score of one or less. In terms of comorbidity, 
NoTreat/Age patients were in good health at diagnosis, with a Charlson comorbidity 
index (CCI) of zero or one (Fig. 3).  
Almost all NoTreat/Age patients had either locally advanced or localized high-risk 
PCa at diagnosis. The median year of diagnosis for all patients was 2003 (IQR 2001-
2007). Median year of diagnosis for patients in the NoTreat/Age group was 2005 and 
for patients in the NoTreat/Other group 2002.  
Fig. 9: Rationales for offering hormone therapy or WW in non-metastatic patients in the 
Vestfold Mortality Study (N=117)  






In addition to dying of PCa, 86 percent of patients in the NoTreat/Age group 
developed local complications during the course of their disease.  More than half of 
the patients needed bladder catheterization, twenty percent a nephrostomy and ten 
percent a colostomy (see fig. 10).  
Nineteen percent of patients received radiation to the bone (N=8), 7 percent were 
treated with docetaxel alone (N=3) and 14 percent were treated with various 
combinations of palliative therapies. Almost 60 percent of NoTreat/Age patients 
received neither docetaxel nor radiation to the bone nor any other second-line 
treatment (N=25). Only one patient (2%) received abiraterone alone and no patient 
received enzalutamide alone. Forty-seven percent of NoTreat/Age patients (N=20) 




Fig. 10: Local complications during the course of the disease in patients with no 
local/ curative treatment due to age (NoTreat/Age, N=43). The total incidence of 





4.3.2 National data on treatment in elderly NMPCa patients, 2009-17 
Among the 1874 CRN patients (age ≥ 75 years, WHO functional status 0, high-risk or 
locally advanced PCa, diagnosed 2009-2017), 748 patients had received local 
treatment of the prostate. There were 152 PCa deaths, 12 among patients with local 
treatment and 140 among patients without local treatment.  
There was a significant survival benefit for patients aged 75-79 years who had 
received local treatment with a 5-year cause-specific survival of 99 percent (CI 97-
100) versus 91 percent (CI 87-94, p<0.001). A similar difference was observed for 
patients aged 80+ with a 5-year cause-specific survival of 95 percent (CI 82–99) 























5.1 Metastatic, castration-resistant prostate cancer (mCRPC) - 
Paper I 
In a cohort of 130 consecutive patients with mCRPC at Vestfold Hospital Trust during 
the six-year period 2000-2005, we examined the natural course of this preterminal 
stage of PCa, which is heterogeneous. In order to address the need for risk-
stratification of patients with mCRPC, we aimed to provide easily accessible, 
statistically independent prognostic factors from an unselected, population-based 
cohort of patients.  
The median survival of approximately one year illustrates that mCRPC without life-
prolonging treatment is a condition with a grim prognosis for the majority of patients. 
We identified a subgroup of mCRPC patients (6%, N=8) with extremely rapid 
progression of the disease whose median survival after the onset of mCRPC was only 
five months. These patients had virtually no effect of ADT (median effective hormone 
time 3 months) prior to the onset of mCRPC. On the opposite side of the spectrum we 
found a considerable number of long-time survivors with a survival time of three years 
and more following the onset of mCRPC (17%; N=22) which means that survival 
shows very heterogenous trajectories in patients with mCRPC (see fig. 7). 
This “true natural course” of mCRPC without life-prolonging treatment other than 
ADT, was what nearly all patients had to face a mere fifteen years ago.  
 
The landscape of mCRPC has changed considerably since. We conducted our study 
after the introduction of new therapeutic agents, which had demonstrated survival 
benefits for patients with mCRPC (see chapter 1.5.3). The trials investigating 
docetaxel (121, 122), abiraterone (138) and enzalutamide (139) as well as radium-223 
(ALSYMPCA) (128) used control patients with mCRPC who received placebo and 





across these five trials should have been similar. However, median overall survival in 
the control groups ranged from eleven to thirty months. 
Crossover from placebo to treatment arms and subsequent antineoplastic treatment was 
permitted in some trials and may explain some of the longer survival times.  
However, bearing in mind the very heterogeneous trajectories of mCRPC patients that 
we documented in our study, one can also speculate that in the trials with the longest 
survival, patients were included during the early stages of mCRPC, while the contrary 
may have been the case in the trials with shorter survival. A further explanation for the 
considerable survival differences between our study and the abovementioned 
randomized clinical trials may be that patients with the most rapid progression of 
mCRPC and very short survival times identified by our study, were probably not 
included in any clinical trial. Table 4 lists treatment details and median survival of the 
abovementioned trials. 
 
Table 4:  Median survival of patients in the placebo arm of pre- and post- docetaxel 
trials.  
 




SWOG 99-16  
(122) 
Docetaxel antineoplastic therapy 









Enzalutamide  antineoplastic therapy 
permitted, cross-over to trial 





Abiraterone Docetaxel permitted on 
progression, cross-over to trial 





Radium 223 Majority of patients post- 
docetaxel (57%), post-trial 








There have been repeated attempts to risk-stratify patients with mCRPC by prognostic 
factors resulting in the publication of several nomograms (140-143). When we 
evaluated these historic nomograms, we found that they incorporated patient 
populations with largely symptomatic mCRPC. The median survival was accordingly 
low (8-16 months from inclusion). With late stage selection being a significant issue in 
these older studies, it was doubtful that they were representative for current mCRPC 
patients who are usually seen at an earlier phase of mCRPC. Since the subjects 
incorporated in these nomograms were all participants in clinical trials at major 
referral centers, we also suspected a significant level of selection bias in patient 
populations. We thus clearly identified a need to better describe patients with mCRPC 
on a population-level and to provide risk-stratification tools to better predict individual 
risk and allow for better randomization procedures in clinical trials.  
 
In our study, we confirmed the value of hemoglobin and alkaline phosphatase levels as 
prognostic markers. Low hemoglobin levels and high alkaline phosphatase levels 
likely reflect extensive cancer infiltration of bone marrow and are probably therefore 
associated with a poor prognosis. Short PSA doubling times after the onset of mCRPC 
and insufficient PSA nadir during ADT showed further negative impact on survival in 
our multivariate analysis.  
Patients with the shortest survival times (< 6 months) were thus defined by PSA nadirs 
during ADT of more than >11 µG/L, PSA doubling times of less than 1.6 months, 
alkaline phosphatase above normal (>105 U/L) and low hemoglobin levels (<13.5 
G/dL) at mCRPC. In clinical practice, patients with these characteristics would likely 
need early and aggressive treatment in order to delay the invariably fatal course of the 
disease. On the other hand, long-term survivors were characterized by excellent ADT 
responses with PSA nadirs ≤1 µG/L, PSA doubling times > 3 months and normal 
hemoglobin and alkaline phosphatase levels at the onset of mCRPC. With median 
survival times of three years, aggressive therapy may be delayed in these patients and 






The introduction of new therapeutical agents in the hormone-naïve setting since the 
publication of our study may have affected the natural course of mCRPC as we 
defined it. Three trials, CHAARTED (27), GETUG-AFU15 (117) and STAMPEDE 
(118), addressed the role of early docetaxel in addition to ADT (see chapter 1.4.2) with 
significant benefits in OS in CHAARTED and STAMPEDE. As a result, docetaxel 
upfront in combination with ADT is now SOC in patients with hormone-naïve M1 
disease. Similar results for abiraterone were documented in the LATITUDE (119) and 
STAMPEDE trial (120).  
With their documented effect on the course of PCa in terms of overall survival, it is 
likely that these agents and their use prior to the onset of mCRPC also affect the 
course of mCRPC. The validity of our prognostic factors will thus need to be 
evaluated anew under the changed circumstances.   
However, despite the need for adjustment, it is likely that the prognostic factors we 
suggest still retain their usefulness for the clinician who needs to address individual 
patient risk.  
 
A further aspect of paper I deserves notice:  Among the 130 patients included in this 
study, 44 patients had non-metastatic disease (NMPCa) at diagnosis. Although this 
study does not further elaborate on how advanced these tumors were, it is striking that 
only one of the 44 NMPCa patients had received radical treatment. Patients were 
diagnosed with PCa between 1991 and 2005 and it is possible that the apparent 
underuse of radical treatments reflect the fact that surgery and radiotherapy were not 
yet firmly established treatment modalities in Norway for many study patients at the 
time of diagnosis. However, it is also possible that the inclusion criteria for radical 
treatment at the time did not reliably identify patients who were at real risk of 








5.2 Defining prostate cancer death – Paper II 
During the process of identifying patients with mCRPC in paper I, we evaluated the 
medical records of all patients with PCa during the study period (N=1460). The death 
certificates of the deceased patients that were available for review, raised quality and 
validity concerns. 
In paper II, we documented that in a cohort of 328 consecutive patients with PCa listed 
as cause of death on the death certificate, one-third died of other causes.  In contrast, 
among 436 patients with PCa whose death certificate indicated that they died of other 
causes, approximately one-tenth died of PCa. The net result was a considerable over-
registration of PCa deaths in Vestfold County during the years 2009–2014. 
Our study therefore casts considerably doubt on the validity of official PCa mortality 
statistics. The problem is exacerbated by our findings that misattribution rates were 
largest in the oldest age groups (see fig. 7) who represent the large majority of PCa 
deaths.  
 
PCa mortality is reported as an age-adjusted number.  In order to understand age-
adjusted PCa mortality as an outcome it is important to understand the process and the 
data it is based upon. The terms that are used can be confusing. The following text and 
figures illustrate the process in which absolute mortality numbers are first computed 
into age-specific death rates and finally into age-adjusted death rates. Figure 11 
shows the absolute numbers of PCa deaths in Norway in 2002 (blue columns) and in 
2013 (red columns).  
In most age groups, there was an increase in PCa deaths over this twelve-year period, 
with the exception of three age groups that saw slight decreases (50-54 yr, 60-64 yr, 
80-84 yr) and one age groups with a large decrease (75-79 yr).  
In order to acquire age-specific mortality rates, PCa mortality numbers from each age 
group are divided by the number of men in the respective age group in Norway (total 
number of men at risk) and then multiplied by 100 000. Figure 12 illustrates the 
resulting age-specific mortality rates for each age group for the same PCa populations 





We now see a decline in age-specific PCa mortality rates in almost every age group 
with the most pronounced changes between the ages of 75 and 94 years. This decline 
is –except for age group 75-79 years- mostly caused by an increase of the population 
at risk (denominator of the rate calculation), rather than a decline in absolute mortality 
numbers (numerator of the rate calculation).  
A "standard" population distribution is finally used to adjust the age-specific rates. 
Several standard populations have been introduced; the most commonly used is the 
WHO standard population (144). The Cancer Registry of Norway (CRN) uses a 
Norwegian standard (mid-year population in 2014) (10). The resulting age-adjusted 
rates are rates that would have existed if the population under study had the same age 
distribution as the "standard" population. In our example, age-adjusted PCa mortality 
in 2002 was 56/ 100 000, while it decreased to 50/100 000 in 2013.  
In spite of the final age-adjustment, it is important to realize that changes in age-









Fig. 11: Absolute numbers of PCa deaths in Norway per age group in 2002 (blue) 
and in 2013 (red); Source: Statistics Norway (Statistisk Sentralbyrå, SSB) 
Fig. 12: age-specific PCa death rates (per 100 000 men) in Norway per age group in 





As mentioned above, the decrease in PCa mortality that has been observed in Norway 
between 2002 and 2013 was most pronounced in the oldest age groups in which we 
documented the largest misattribution rates of PCa deaths. Changes in PCa mortality 
should therefore be interpreted with caution. However, there is an inclination among 
urologists and oncologists to see improvements in PCa mortality exclusively as a 
consequence of improved screening and treatment methods (145). This is also 
illustrated by the reactions to the most recent report of cancer statistics in the US 
which showed a slight increase in PCa mortality for the first time since the early 
1990’s (146). The immediate responses on social media by respected capacities in PCa 
treatment suggest that this slight increase in PCa mortality is seen as a consequence of 
reduced PSA screening after the implementation of the D-recommendation by the 
USPSTF (147, 148). However, a recent review of modeling studies that analyzed 
population trends and extrapolated results from clinical trials, concluded that PSA 
screening can explain only 45% of the PCa mortality decline in the US while changes 
in primary treatment can explain 33% (47). This would leave 20% of the mortality 
decline unexplained. It is also unclear in which age groups the recent increase in PCa 
mortality occurred, as misattribution of cause of death may be one possible 
explanation. However, the misattribution rates for PCa as cause of death in the US are 
unknown.  
Temporal changes of the underlying risk of PCa death in the male population, 
independent of screening and early treatment (reduced risk in the population at risk) 
and insufficient quality of death certificates can all lead to significant distortions of 
mortality statistics. This is especially important when interpreting the apparently high 
PCa mortality in Norway compared to other Western countries (149, 150).  
It is possible that these differences are due to genetic factors (151). However, with the 
current definitions of genetic PCa (17), one would expect higher PCa mortality among 
men younger than seventy years in Norway compared to e.g. the United States. Yet 
differences in age-specific mortality rates between the two countries first become 






Although one cannot rule out that genetic dispositions or different screening and 
treatment policies are the main cause of this surplus PCa mortality, our results imply 
that it can partly be explained by over-reporting of PCa deaths.  
 
The doctor who confirms the patient’s death must fill out death certificates in Norway. 
These are usually junior hospital doctors or on-call doctors at the municipal primary 
care emergency departments (Legevakt) and nursing homes, who rarely have intimate 
knowledge of the patient’s medical history. In contrast to the Norwegian practice, in 
the US the coroner’s office determines the cause of death while in Germany the family 
doctor makes the decision. It is possible that the latter systems result in improved 
cause of death determination. 
 
The increasing age of PCa patients seems to have impacted this problem further: The 
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Fig. 13: Age-specific PCa mortality rates (per 100 000 men) for Norway (red) and 
the US (blue) in 2013 
Source: Statistics Norway (SSB, Norwegian data), Center for Disease Control and 






the cause of death is usually more accurate (152), while only one third occurred in 
nursing homes. By 2014, these numbers were reversed, with more than 60% of PCa 
deaths occurring in nursing homes and only 23% in hospitals (2016 mail 
correspondence with the Norwegian Institute of Public Health).  
 
Our findings of subpar PCa death reporting stand in contrast to earlier studies, which 
showed that PCa mortality statistics based on death certificates, were relatively reliable 
in Norway (153, 154). However, these studies were register-based without access to 
patient records. Furthermore, they evaluated PCa deaths that occurred in 1996, prior to 
the considerable increase in PCa prevalence that has been observed since. PCa 
prevalence in this context appears to have a clear impact on PCa mortality: Studies 
from the early PSA era in the US showed that rising and falling PCa prevalence rates 
were mirrored directly by corresponding changes in mortality rates (155). The most 
likely explanation was that a fixed percentage of the rising and falling pool of newly 
diagnosed PCa patients was mislabeled as dying of the disease.  If similar 
misattribution mechanisms apply to Norway, then misattribution rates have likely 
increased considerably during the past fifteen years which have seen a doubling of 
PCa prevalence in Norway, probably due to increasing PSA testing (8).  
Further publications of death certificate audits are available from Finnish, Swedish and 
UK PCa trials (156-159). They consistently show high accuracy of death certificates, 
while a similar evaluation in a group of PCa patients in the US showed more 
ambivalent results (131). However, PCa deaths that were evaluated in these studies 
occurred within the framework of clinical trials and patients were on average 
significantly younger at death than PCa patients in the general population (maximum 
age at death 74–77 years in the Finnish and Swedish trials versus median age  at death 
83 years in the Norwegian population).  
 
There is a further aspect of PCa death that may be controversial: That not every PCa 
death is an event that must be prevented. The in-depth review of patient histories that 





but also sometimes a welcome and natural end to a long life. This is mirrored both by 
the fact that almost twenty percent of patients had dementia at the time of death and 
the abovementioned high percentage of patients who die at nursing homes. Many of 
the patients also had several competing comorbidities with short expected survival. 
The concept of “acceptable” PCa death is difficult to define in an academic setting and 
it is not incorporated in our prediction tools. However, it is an important aspect to 
address when patients have to weigh the side effects of early treatment against the 
benefit of reducing their risk of dying of PCa.  
 
Finally, enforcing our findings from paper I, we documented that only a small number 
of patients with NMPCa at diagnosis and potentially curable disease had received 
radical treatment (16%). This consistent finding led to the more thorough investigation 
of the rationales behind decision treatments for patients with NMPC that represents the 
background for paper III.  
 
 
5.3 Treatment decisions and consequences in elderly prostate 
cancer patients – Paper III 
We documented in this study that many patients with lethal PCa but potentially 
curable disease at diagnosis did not receive radical treatment based on their 
chronological age alone (≥75 years).  In addition to dying of PCa, most of these 
patients experienced considerable morbidity caused by local PCa complications. Our 
analysis of national data suggest that local treatment of elderly PCa patients with good 
functional status may reduce PCa specific mortality (PCSM).  
 
There is increasing evidence that elderly cancer patients in general are undertreated, 
particularly with regard to local, curative therapy (160-162). In PCa, elderly men with 
NMPCa have been treated with hormone therapy or followed with watchful waiting, 
partly due to the lack of documented benefit of radical treatment (163). In our study, 





status) for radical treatment ten to fifteen years ago, excluded patients that would be 
eligible for radical treatment according to current guidelines (17). 
 
Contradicting the notion that NMPCa in elderly patients is harmless, there is 
increasing evidence that locally advanced and high-risk NMPCa is often deadly 
regardless of age. A US study, based on SEER-Medicare data, demonstrated a 10-year 
PCSM of 27 percent for patients ≥75 years with high-risk, localized PCa (164). In 
Sweden, a register-based study found that even in patients ≥85 years, untreated, locally 
advanced PCa with Gleason 8-10 was associated with a mortality rate of 42 percent 
(46).  
The nationwide data from our study suggest that effective local treatment of the 
prostate may reduce PCSM in patients ≥75 years. Several other studies support this 
notion. A Swedish, nationwide, register-based study indicated that radiotherapy had 
the potential of improving PCSM in elderly patients (165). Sheng and colleagues also 
found a positive impact of local treatment on PCSM in elderly American patients 
(aged ≥ 75 years, locally advanced PCa, SEER database). However, the benefit was 
only seen in patients with cT3b/4 tumors, Gleason score 8–10, negative lymph nodes 
or PSA > 10 ng/ml (166). In Australia, a register-based study also found that radical 
treatment reduced the risk of PCSM even in patients >80 years (167). 
 
The risk of developing high-risk and locally advanced PCa increases with age (46, 
168). Somewhat paradoxically, elderly men with PCa are less likely to receive radical 
treatment (165, 169). A recent publication of data from the US National Cancer 
Database (NCDB) documented that increasing age was significantly associated with 
decreased likelihood of radical treatment in patients with intermediate and high-risk 
PCa. Interestingly, despite the claim of undertreatment of the elderly, the study 
showed that more than half of patients older than 80 years had received some form of 
local treatment, mostly radiotherapy (170). This contrast sharply with treatment 
policies in Norway: While in 2004, less than five percent of patients aged 75-79 years 





twelve years (~50% radical treatment in 2016). However, even in 2016 only slightly 
more than 10 percent of patients older than 80 years had received radical therapy 
(radiotherapy, ≥70Gy, ≤12 months of diagnosis) (8). This appears to have been even 
more pronounced in Sweden. In a nationwide cohort study with over 120 000 men 
aged 55 to 95 years, diagnosed with PCa in 1998 to 2012, virtually no man >80 years 
had received radical treatment (171). 
 
What may be the reason for the apparent reluctance to treat elderly patients with 
NMPCa radically? First, it is possible that findings from SPCG4 left the impression 
that radical treatment did not confer a survival benefit for patients older than 65 years 
(81). However, most patients included in SPCG4 had intermediate-risk PCa and the 
results should therefore not be extrapolated to patients with high-risk or locally 
advanced PCa. Of note, SPCG4 demonstrated reduced incidence of metastasis and 
ADT use also in patients older than 65 years.  
Furthermore, none of the major randomized clinical trials on radical treatment versus 
hormone therapy or watchful waiting included patients older than 75 years (81-83, 
172). Only one of the randomized trials investigating radiotherapy in combination with 
ADT versus ADT alone included patients 75-80 years of age (173). This leaves us 
with no level 1 evidence for determining the role of radical treatment in the elderly. 
A further reason for deferring radical treatment is underestimation of patients’ life 
expectancy (174, 175). The background for this may be a misconception about life 
expectancy statistics in general. In most Western European countries life expectancy 
for men is somewhere in the range between 77 and 80 years (176). Intuitively, treating 
patients in this age group radically with little documented benefit of treatment for the 
first years can seem futile and unnecessary. However, the abovementioned life 
expectancy numbers refer to life expectancy at birth. Life expectancy later in life is a 
different matter. For example, a 75-year-old Norwegian man in 2018 had a mean life 
expectancy of 11.7 years, while an 80-year-old still had a mean life expectancy of 8.5 





Local complications of PCa have been a focus area with regard to treatment effects 
(100) but there is little literature on complications caused by uninhibited local tumor 
progression. This aspect of the disease is difficult to address in registry-based studies 
that do not have access to these kind of data. An unintended consequence could be that 
complications and side effects caused by treatment receive more consideration when 
we give advice to patients than complications caused by local, uninhibited tumor 
growth. 
We documented in our study that almost all of the elderly NMPCa patients that had 
not received local treatment of the prostate experienced some form of local 
complication during the further course of the disease. Local treatment of the prostate 
has the potential to alleviate or even avoid these complications altogether. However, 
the possible benefits of treatment must be weighed against the side effects. Ideally, the 
issue should be addressed in the setting of a clinical trial.  
 
Our findings lend further support to the notion that elderly patients who are in good 
health and have good functional status and who are diagnosed with high-risk or locally 
advanced PCa should be considered for radical therapy regardless of their 
chronological age.  Future clinical trials investigating the effects of local treatment 







6. Strengths and limitations 
6.1 Strengths 
All three papers describe patient populations from Vestfold County, which only has 
one department of urology and had no urologists or oncologists in private practice at 
the time. This allowed for a comprehensive analysis of patient records and for access 
to high-quality data despite the retrospective design of the studies. All analyses were 
performed in consecutive and unselected patient groups.  
In paper II, the direct access to patient records instead of registry information provided 
a high level of accuracy in determining patients’ cause of death.  
The CRN data in paper III allow for an extended view on a nation-wide level. CRN 
has coverage of more than 99 percent of cancers in Norway (177) which means that 
analyses of CRN data can be performed with a high degree of accuracy.  
 
6.2 Limitations 
The comparatively small size and regional restriction of the patient population in 
Vestfold County are limitations, particularly with regard to the generalizability of our 
finding to the national level.  
Furthermore, the retrospective nature of our analyses prohibited the collection of some 
important data. This was a limiting factor particularly in paper I, in which we could 
not quantify metastatic burden and describe metastatic sites. The medical records 
lacked systematic documentation of patient performance and pain status, which are 
established prognostic factors. Furthermore, the calculations of PSA doubling times 
and description of PSA nadirs were probably influenced by the variation of time 
intervals between analyses, which is a major difference between clinical trials and 
daily clinical practice that our analyses were based upon.  
Furthermore, the imaging studies used at the time (mostly bone scans) may have 






Furthermore, the 38 patients who had received docetaxel as second line treatment and 
who were excluded from paper I were younger at diagnosis and at mCRPC, which 
may have biased the results. A further limitation of paper I was that not all parameters 
were available for every patient. However, MCMC multiple logistic regression 
imputation showed that this did not significantly affect the Cox multivariate analyses.  
In paper II, the clinical decision-making process to identify the correct cause of death 
was potentially biased. This may have led to either over-estimation or under-
estimation of PCa mortality.  
The committee members in this study treated PCa patients daily. A different mix of 
specialties may have led to different conclusions for some of the patients.  
Paper III makes a point for providing more local treatment of the prostate in elderly 
patients, but does not provide a measure of overtreatment such an approach would 





7. Conclusions; Prostate cancer morbidity and mortality in 
Norway 
The three papers in our study demonstrate that defining late stage PCa and describing 
and interpreting PCa mortality correctly is complex. Several lessons and conclusions 
can be drawn from our work: 
 
 Late stage PCa (mCRPC) is a heterogeneous condition with diverse survival. 
 Its natural course can be defined by easily accessible parameters 
 PCa death reported on death certificates is unreliable particularly among the 
elderly and it is unsuitable as a stand-alone outcome measure in Norway  
 There are indications of undertreatment at diagnosis both in patients who later 
develop late-stage PCa and in patients who die of PCa. 
 Decisions with regard to radical treatment for patients with NMPCa are unduly 
influenced by patient age and by underestimation of patient life expectancy 
 The majority of elderly patients with high risk or locally advanced NMPCa not 
treated with local therapy suffer considerable local complications 
 PCSM in elderly patients who are in good health, who present with good 
functional status and who are diagnosed with high risk or locally advanced 
NMPCa may be reduced with local therapy  
 Randomized, clinical trials investigating the effects of local treatment of PCa 













8. Future perspectives 
 There is a need to supplement PCa mortality with other public health outcome 
measures. To this purpose, a nation-wide registry of patients who have late-
stage PCa and who receive life-prolonging oncologic treatment could be 
established. Such a registry has several advantages over PCa mortality as a 
stand-alone measure. First, very old and frail patients who die of PCa at e.g. 
nursing homes and who are unsuited for active oncologic treatment would not 
be registered. This would introduce some differentiation of PCa death, between 
death that is “natural” and death that should be prevented if possible. Second, 
risk-stratification models could be better tailored to identify patients who are at 
risk for developing late-stage PCa and the need for active oncologic treatment 
rather than patients who are at risk of a “natural” PCa death. Finally, the 
suggested registry would enable a continuous evaluation of treatment effects, 
treatment side effects and disease-related side effects over time.  
 
 We identified the need for a randomized clinical trial investigating local 
treatment versus no local treatment in NMPCa patients ≥75 years who have 
normal functional status and good health. Such a trial would give better 
guidance on who would benefit from treatment, give a measure of 
overtreatment and clarify the potential of local treatment to reduce PCa 
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ABSTRACT
Objective: This study aimed to determine the level of misattribution of prostate cancer deaths in
Norway based on the county of Vestfold in the years 2009–2014.
Materials and methods: The study included 328 patients registered as dead from prostate cancer
(PCD; part I of death certificate), 126 patients with prostate cancer as other significant condition at
death (OCD; part II of death certificate) and 310 patients who died with a diagnosis of prostate cancer
not registered on the death certificate (PC-DCneg) in Vestfold County in 2009–2014. The complete
cohort with patients’ names and dates of birth was provided by the Norwegian Institute of Public
Health and the Norwegian Cancer Registry. The true cause of death of all patients was evaluated based
on patient journals.
Results: Over-reporting of prostate cancer deaths in the PCD group was 33% while under-reporting in
the OCD and PC-DCneg groups was 19% and 5%, respectively. The correlation between registered and
observed causes of death was 0.81 (95% confidence interval 0.78–0.83). Misattribution of prostate can-
cer deaths increased significantly with patient age and decreasing Gleason score.
Conclusions: Prostate cancer mortality statistics in Norway are relatively accurate for patients aged
<75 years at death. However, overall accuracy of cause of death assignment is significantly reduced by
misattribution among older patients (> 75 years), who represent the large majority of prostate cancer
deaths. Over-reporting of prostate cancer deaths among elderly people may not be an exclusively
Norwegian phenomenon and may affect prostate cancer mortality statistics in other countries.
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Official cancer mortality statistics strongly influence the per-
ception of different cancers, their impact on public health
and the effects of treatment efforts [1]. The accurate deter-
mination of cancer deaths and high quality of death certifi-
cates are essential for achieving reliable mortality statistics.
However, such high-quality information is commonly only
available in clinical trials or hospital series.
Norway and other Scandinavian countries report consist-
ently higher prostate cancer mortality rates than other
Western countries [1,2]. Several explanations for this have
been suggested, among them a potentially higher underlying
risk of prostate cancer death and differences in national
health strategies regarding screening and treatment [2]. In
1981, Percy et al. documented that misattribution of cause of
death in death certificates may bias mortality statistics [3].
Several studies have since corroborated this evidence [4–6].
For prostate cancer, there is compelling evidence that
increasing prevalence due to screening has significantly
affected misattribution of prostate cancer deaths [7].
Several Scandinavian studies have addressed the quality
of death certificates with regard to prostate cancer, demon-
strating relatively reliable results with misattribution rates of
10% or less [8–11]. However, previous audits of prostate can-
cer deaths have been either registry based [10,11] or con-
ducted in study patients who were considerably younger at
death than the majority of men dying of prostate cancer
[8,9]. Correct attribution of the underlying cause of death
becomes more challenging with increasing age owing to
competing comorbidities [12]. A recent Norwegian study,
comparing relative and cause-specific survival for several can-
cer sites, documented significant differences for older pros-
tate cancer patients, suggesting incorrect coding of the
underlying cause of death [13].
Increasing prostate cancer incidence rates in Norway and
the likely corresponding increase in prevalence of non-lethal
cancers may potentially exacerbate this problem of misattri-
bution bias.
The aim of this population-based study was to determine
the level of misattribution of Norwegian prostate cancer
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Vestfold Hospital Trust is the only hospital in Vestfold
County, which has approximately 230,000 inhabitants repre-
senting approximately 5% of the Norwegian population.
Vestfold County has a somewhat higher proportion of men
older than 70 years than the rest of Norway, but is otherwise
representative of the entire country in terms of relevant soci-
oeconomic factors (see supplementary material).
For the 6 year period 2009–2014, names and dates of
birth of all deceased men in Vestfold County, registered with
either prostate cancer as the immediate/underlying cause of
death (part I of the death certificate, n¼ 341) or another sig-
nificant condition at death (part II of the death certificate,
n¼ 127), were obtained from the Norwegian Institute of
Public Health, while data on all deceased men with prostate
cancer whose diagnosis was not mentioned on the death
certificate were obtained from the Norwegian Cancer
Registry.
Prostate cancer care for almost all patients in the county
of Vestfold is provided at Vestfold Hospital Trust, including
diagnosis, treatment and follow-up. Patients from two periph-
eral municipalities, who routinely receive their prostate can-
cer care elsewhere, were excluded from the study. This
resulted in a study population of 328 patients with prostate
cancer as an immediate or underlying cause of death (part I
of the death certificate), referred to as PCD; 126 patients with
prostate cancer as other significant condition (part II of the
death certificate), referred to as OCD; and 310 patients with
prostate cancer without any mention of prostate cancer on
the death certificate, referred to as PC-DCneg (Norwegian
Cancer Registry).
Assessment of cause of death
A review committee was formed consisting of three urolo-
gists and one oncologist, all of whom were experienced in
treating prostate cancer patients. Three consecutive reviews
of the study population were conducted. Patient hospital
records provided sufficient information on medical histories
for the great majority of patients. For 12 patients, additional
information had to be obtained from nursing homes or fam-
ily doctors.
First review of patient history
The first review served as a filtering process and identified
patients with an unambiguous, immediate cause of death
and a clear underlying disease process, separating out
patients ascribed as either dead from prostate cancer (PCD)
or dead from other causes (OCD). The review was conducted
by the first author, with a blinded audit of 50 random
patients in the sample by two other committee members
demonstrating perfect correlation.
Prostate cancer death was assumed when the immediate
cause of death was caused by systemic or local complications
of the disease process or cancer-directed treatment and
comorbidities were either absent or only of minor import-
ance. Death from other causes was defined by the criteria
listed in Table 1.
Patients who could not be placed with certainty in either
of the above categories were included in the second review
for further evaluation.
Patients who had been autopsied were registered with
the underlying cause of death given on the autopsy report,
and no further review of the cause of death was conducted
(n¼ 16).
Second review of patient history
Patients were independently reviewed by committee mem-
bers unaware of the other reviews. Prostate cancer death
was assumed when the immediate cause of death was due
to systemic or local complications of the disease process or
cancer-directed treatment. The following categories were
assigned, answering the question of whether the patient’s
death was due to prostate cancer: ‘Yes/No’ (preferable cat-
egory), ‘Likely/Unlikely’ (if a definite answer was not possible)
or ‘Not possible to determine’ (if any qualified answer was
impossible to give, owing to numerous and competing
comorbidities). Patients on whom committee members
reached conflicting conclusions were included in the third
review.
Third review of patient history
Patients whose underlying cause of death was still undeter-
mined after the first two reviews were discussed in a consen-
sus meeting with all members of the committee present.
Patient histories were reviewed in plenum and a consensus
decision was reached upon which all committee members
could agree. Assignment of labels followed the same rules as
outlined under the second review of patient history.
Final result
All patients with the label ‘Yes’ or ‘Likely’ after the third
review were collapsed into the final Yes category (dead from
prostate cancer). Patients labeled ‘No’ or ‘Unlikely’ were
Table 1. First review of patient history: definition of death from other causes
for patients with prostate cancer as underlying of immediate cause of
death (PCD, n = 328) and corresponding results.
No. of patients (%)
No histological or clinical diagnosis of prostate
cancer
15 (4.6)
Watchful waiting with no significant disease activity 13 (4)
Previous radical treatment with no disease recur-
rence and an immediate cause of death not
related to treatment
5 (1.5)
Hormone therapy with complete response to treat-
ment and an immediate cause of death unrelated
to hormone therapy, and other
33 (10.1)
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collapsed into the final No category (not dead from prostate
cancer). ‘Not possible to determine’ was upheld as an inde-
pendent category.
Statistics
Baseline data and prostate cancer death misclassification
rates were described by median, range and percentages.
Confidence intervals (CIs) for percentages were calculated
using Wilson score interval with Yates’ continuity correction.
The effect of age and study year on the risk of misclassifying
cause of death was studied by binary logistic regression.
Subgroup analysis was performed by dividing patients into
seven age groups (< 65, 65–70, 70–75, 75–80, 80–85, 85–90,
and >90 years). All statistical analyses were conducted using
SPSS statistics, version 23 (IBM Corp., Armonk, NY, USA) and
the R statistical package [14]. Correlation between the cause-
of-death methods was calculated using Cohen’s kappa.
Ethics
The study was approved by the Regional Committee for
Medical Research Ethics (REK).
Results
The median age at death was 83–84 years in all groups. In
the PCD group, 21% of patients were younger than 75 years
at death, with corresponding numbers of 14% in the OCD
group and 16% in the PC-DCneg group (n¼ 70, n¼ 18,
n¼ 50), while 14% of patients in the PCD group, 20% in the
OCD group and 14% in the PC-DCneg group were older than
90 years at death (n¼ 46, n¼ 25, n¼ 43). Dementia had been
diagnosed in 18% of the PCD patients, 11% of the OCD
patients and 10% of the PC-DCneg patients (n¼ 58, n¼ 14,
n¼ 32). Fifteen patients in both the PCD and OCD groups
and two patients in the PC-DCneg group had no clinical or
histological diagnosis of prostate cancer. The clinical charac-
teristics of all patients are listed in Table 2.
Death from prostate cancer (PCD)
The first review of the PCD group identified 21% of patients
(n¼ 70) who had died of causes other than prostate cancer.
Their prostate cancer status at death is listed in Table 1. The
final result of the review process demonstrated that 32% of
Table 2. Comparison of clinical characteristics of patients with prostate cancer as the immediate or underlying cause of
death according to the death certificate (PCD), patients with prostate cancer as other significant condition at death (OCD)
and patients with prostate cancer with no mention of the diagnosis on the death certificate (PC-DCneg).
PCD patients OCD patients PC-DCneg patients
All patients
No. of patients 328 126 310
Age at death (years) 84 (50–97) 84 (59–98) 83 (57–101)
Patients with prostate cancer
No. of patients 313 111 308
Year of diagnosis 1989–2014 (2007) 1988–2014 (2005) 1985–2013 (2005)
Age at diagnosis (years) 76 (48–96) 76 (52–93) 75 (55–96)
Age at death (years) 83 (50–97) 83 (59–98) 83 (57–101)
PSA at diagnosis (mg/l) 34 (0–10 000) 21 (1–2853) 15 (0–4400)
Gleason score at diagnosis
 6 29 (9) 23 (21) 106 (35)
7 102 (33) 36 (32) 119 (39)
8–10 128 (41) 34 (31) 54 (18)
Unknown 54 (17) 18 (16) 29 (9)
T stage
T1 44 (14) 21 (19) 117 (38)
T2 41 (13) 14 (13) 65 (21)
T3 140 (45) 59 (53) 100 (33)
T4 48 (15) 9 (8) 17 (6)
Unknown 40 (13) 8 (7) 9 (3)
Metastatic status at diagnosis
Yes 106 (34) 18 (16) 30 (10)
No 178 (57) 85 (77) 268 (87)
Unknown 29 (9) 8 (7) 10 (3)
Metastatic status at death
Yes 230 (74) 26 (23) 22 (7)
No 63 (20) 84 (76) 279 (91)
Unknown 21 (6) 1 (1) 7 (2)
Primary treatment
Hormone therapy 223 (71) 55 (50) 110 (36)
Radical prostatectomy 11 (4) 9 (8) 26 (8)
Radiation therapy 15 (5) 9 (8) 31 (10)
Watchful waiting 61 (20) 37 (33) 115 (37)
Active surveillance 5 (2)
Autopsy finding 2 (1)
Cystoprostatectomy (bladder cancer) 15 (5)
Other 3 (1) 1 (1) 4 (1)
Time from diagnosis to death (years) 5 (0–22) 6 (0–22) 6 (0–27)
Hormone therapy at death 284 (91) 82 (74) 143 (46)
mCRPC at death 200 (64) 39 (35) 40 (13)
Data are shown as n, median (range) or n (%).
PSA: prostate-specific antigen; mCRPC: metastatic castration-resistant prostate cancer.
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patients (n¼ 105) in the PCD group had died of other causes.
Logistic regression demonstrated a statistically significant
increase in misattribution rates with increasing age in the
PCD group (p< 0.001, OR 1.8 per 5 years, 95% CI 1.4–2.1).
Among patients younger than 75 years, 10% (7/70) were
incorrectly labeled as dead from prostate cancer while the
misattribution rate increased to 63% in patients aged 90
years and older (29/46). Misattribution of cause of death per
age group in the PCD group is illustrated in Figure 1. Logistic
regression revealed a statistically significant impact on mis-
attribution rates by Gleason grade (p¼ 0.007, OR 0.7, 95% CI
0.5–0.9). There was no statistically significant variation in mis-
attribution rates for the years of diagnosis 2009–2014
(p¼ 0.25, OR 1.1, 95% CI 1.0–1.2) or for tumor stage at diag-
nosis (p¼ 0.12, OR 0.8, 95% CI 0.6–1.1).
Death from other causes (OCD)
In the OCD group, the final results of the review process indi-
cated that 18% of patients (n¼ 23) had died of prostate can-
cer. Logistic regression showed a statistically non-significant
decreasing trend of misattribution by age in the OCD group
(p¼ 0.33, OR 1.2 per 5 years, 95% CI 0.9–1.6). Misattribution
of cause of death per age group in the OCD group is illus-
trated in Figure 2. Gleason grade had a statistically significant
impact on misattribution (p¼ 0.006, OR 0.5, 95% CI 0.3–0.8).
There was no statistically significant variation in misattribu-
tion rates for year of diagnosis (p¼ 0.18, OR 0.8, 95% CI
0.6–1.1) or stage at diagnosis (p¼ 0.25, OR 0.7, 95% CI
0.4–1.3).
The review process of PCD and OCD patients and its
results are illustrated in Tables 3 and 4.
Patients with prostate cancer not registered on the
death certificate (PC-DCneg)
Among the 310 PC-DCneg patients, the review process identi-
fied 5% (n¼ 14) who had died of prostate cancer.
Underreporting of prostate cancer deaths in the OCD
and PC-DCneg groups was 18% and 5%, respectively, while
over-reporting in the PCD group was 32% (Figure 3).
The correlation between reported patient death and
observed patient death was 0.81 (95% CI 0.78–0.83), with
Cohen’s kappa (0.4, 95% CI 0.3–0.5) showing a moderate
correlation between registered and true prostate cancer
death.
Discussion
In a cohort of 328 consecutive patients with prostate cancer
as cause of death, this study found that one-third died of
other causes, while among 436 patients with prostate cancer
who died of other causes approximately one-tenth died of
prostate cancer. The net result was a considerable over-regis-
tration of prostate cancer deaths in Vestfold County for the
years 2009–2014.
This study has several strengths: its population-based
design, the consecutive cohort of patients, the 6 year study
period and rich clinical data for the majority of patients. The
weaknesses of the study are its limited geographical scope
and the difficult clinical decision-making process, which
might be biased. The committee members in this study treat
prostate cancer patients daily. A panel of physicians from
other specialties may have come to different conclusions for
some of the study patients.
Figure 1. Total number of patients registered as dead from prostate cancer per age group: patients dead from prostate cancer (blue), patients dead from other
causes (green) and patients whose cause of death was not possible to determine (yellow).
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The findings seem to contradict previous studies which
documented relatively reliable mortality numbers for prostate
cancer in Norway [10,11]. However, these studies were regis-
ter based and evaluated prostate cancer deaths that occurred
in 1996, before the PSA-induced increase in prostate cancer
prevalence. Feuer et al. demonstrated during the early PSA
era that rising prostate cancer prevalence rates were mir-
rored directly by corresponding changes in mortality rates
[7]. The authors hypothesized that a fixed percentage of the
rising and falling pool of newly diagnosed prostate cancer
patients was mislabeled as dying of the disease [7].
According to this theory, it is likely that misattribution rates
in Norway have increased considerably during the past dec-
ade (2004–2013) as prostate cancer prevalence has doubled
at least partly owing to extensive PSA testing [15]. Prostate
cancer prevalence is equal in Vestfold County and on the
national level, suggesting that misattribution rates may be
comparable [16]. A more recent study by the Norwegian
Cancer Registry demonstrated that relative survival estimates
for prostate cancer were consistently above cause-specific
survival estimates for all but the very youngest patients, with
the most marked differences among the oldest patients (>85
years) [13]. One explanation suggested by the authors is that
prostate cancer patients in Norway are somewhat healthier
Figure 2. Total number of patients registered as dead from other causes per age group: patients dead from prostate cancer (blue), patients dead from other causes
(green) and patients whose cause of death was not possible to determine (yellow).
Table 3. Results of the review process for patients with prostate cancer as the immediate or underlying cause of death (PCD) (n¼ 328).
Prostate cancer death
First review Second review Third review Final result
% (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n
Yes 58 (52–63) 189 60 (54–65) 195 62 (56–67) 202 67 (61–72) 218
No 21 (17–26) 70 26 (21–31) 85 29 (24–34) 94 32 (27–37) 105
Likely – – 2 (1–4.5) 7 5 (3–8) 16 – –
Unlikely – – 0.3 (0–2) 1 3 (2–6) 11 – –
Not possible to determine – – 0.6 (0–2) 2 2 (1–4) 5 2 (1–3) 5
Further discussion needed 21 (16–26) 69 12 (8–16) 38 – – – –
CI: confidence interval.
Table 4. Results of the review process for patients with prostate cancer as other significant condition at death (OCD) (n¼ 126).
Prostate cancer death
First review Second review Third review Final result
% (95% CI) n % (95% CI) n % (95% CI) n % (95% CI) n
Yes 14 (8–21) 17 15 (10–23) 19 16 (10–24) 20 18 (12–26) 23
No 66 (57–74) 83 72 (63–79) 90 75 (66–82) 94 79 (70–85) 99
Likely – – 0.8 (0–5) 1 2 (1–7) 3 – –
Unlikely – – 2 (0–6) 2 4 (2–10) 5 – –
Not possible to determine – – 0.8 (0–5) 1 3 (1–8) 4 3 (1–8) 4
Further discussion needed 21 (14–29) 26 10 (6–17) 13 – – – –
CI: confidence interval.
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than the general population. However, as the observed effect
is strongest among the oldest patients, the reported differen-
ces are more likely to be due to incorrect coding of the
underlying cause of death. This is mirrored by the patients in
the present study whose cause of death could not be deter-
mined during the first review: the median age in this sub-
group was 86 years and for the majority a cause of death
could first be determined after the third review. For patients
younger than 75 years, on the other hand, results were rela-
tively reliable, with a 90% concordance between cause of
death on the death certificate and cause of death based on
committee evaluation. However, these patients were a clear
minority in the PCD group (21%), where 75% of patients
were older than 77 years at death.
A further explanation for the high misattribution rates in
this study may be found in the Norwegian proceedings for
death certification [17,18]. In contrast to many other Western
countries, death certificates in Norway are filled out by the
doctor who confirms the patient’s death. These are usually
the most junior doctors at the hospitals or on-call doctors at
the municipal primary care emergency departments and
nursing homes, who rarely have intimate knowledge of the
patient’s medical history. In 1986, 57% of Norwegian prostate
cancer deaths occurred in hospitals, where determination of
the cause of death is usually more accurate [19], while only
29% occurred in nursing homes. By 2014 these numbers
were reversed, with more than 60% of prostate cancer deaths
occurring in nursing homes and only 23% in hospitals (2016
mail correspondence between the Norwegian Institute of
Public Health and the first author). This change may have
impacted the accuracy of death certificates considerably.
Furthermore, it seems that not all doctors are fully confident
with the concepts of immediate, underlying and contributory
causes of death. In addition, the guidelines from the WHO
state that in certain circumstances a specific diagnosis in part
II of the death certificate may be registered as the underlying
cause of death instead of an unspecific diagnosis in part I.
This will have little impact on the actual cause of death in
patients with a cancer diagnosis and few or no comorbidities.
However, in patients with several comorbidities, usually older
patients, this lack of knowledge may have a considerable
impact on accuracy.
A key issue is the interpretation of the results and the
question of whether over-registration of prostate cancer
deaths is a specific Norwegian problem. In this case, prostate
cancer mortality may not be significantly higher in Norway
than in other Western countries. A Swedish registry-based
study, evaluating the quality of official cause of death diag-
noses of prostate cancer patients diagnosed in 1987–1999
and deceased before 2003, documented a relatively high reli-
ability (correlation of 0.86%) of official cause of death statis-
tics [20]. However, the hallmarks of misattribution of cause of
death are similar to those in the present study, with high
correlation among the youngest patients and increasing mis-
attribution with increasing age. The higher misattribution
rates seen in the current study may be due to the more
recent timeframe of this study, with higher underlying preva-
lence rates of prostate cancer.
Further results of death certificate audits have been pub-
lished for Finnish, Swedish and UK prostate cancer patients
[8,9,21,22], demonstrating high accuracy of death certificates
in those countries, while a similar evaluation in a group of
US prostate cancer patients showed more ambivalent results
[23]. However, patients evaluated in these studies were par-
ticipants in clinical trials and were on average significantly
younger at death than prostate cancer patients in the
Figure 3. Patient transition from the original group of patients registered as dead from prostate cancer (PCD) and formation of the group of patients observed
dead from prostate cancer. OCD: dead from other causes; PC-DCneg: prostate cancer not registered on the death certificate.
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general population (maximum age at death 74–77 years in
the Finnish and Swedish clinical trials). The majority of pros-
tate cancer deaths occur in patients older than 80 years and
thus similar quality issues as described in the present study
may negatively affect the prostate cancer mortality statistics
in the above-mentioned countries. In this case, prostate can-
cer mortality may still be relatively high in Norway, with
excess mortality among patients older than 80 years. This
may be due to national therapy recommendations where,
until recently, a strict age limit (75 years) for recommending
radical therapy has been observed.
Prostate cancer mortality statistics in Norway must be
interpreted with caution and may have to be supplemented
by additional parameters (e.g. statistics on patients with cas-
tration-resistant prostate cancer) that may better reflect dis-
ease burden and intervention effects in the general
population.
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